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Abstract 
The rapid increase in antibiotic resistant infections and the slowing pace of antibiotic 
development emphasize the need for alternative therapeutic agents to cure infectious diseases 
especially those caused by multidrug-resistant (MDR) strains. Bacteria obtain resistance to 
antibiotics through multiple mechanisms. One of intrinsic mechanisms of drug resistance is 
persister formation, by which bacterial cells enter a metabolically inactive stage and become 
highly tolerant to essentially all antibiotics, even at the concentrations that are hundreds of times 
higher than the lethal dose required to kill normal planktonic cells of the same strain. Persister 
cells in biofilms are even more difficult to kill due to the presence of an extracellular matrix that 
can block or retard the penetration of antibiotics. Thus new antimicrobials that are effective 
against these drug tolerant cells are urgently needed for infection control. 
In this study, we characterized the antimicrobial activities of newly designed synthetic peptides 
on Escherichia coli and Pseudomonas aeruginosa strains including regular planktonic cells and 
those in biofilms and at the persister stages. Our results revealed that 2D-24, an RW-rich 
dendrimeric peptide, can kill planktonic cells of both P. aeruginosa PAO1 and PDO300 (a 
mucoid strain) in a dose-dependent manner. Killing effect on biofilm and persister cells was 
observed at the concentrations without significant toxicity to IB3-1 cells originated from human 
lung tissues.  
We also demonstrated that TN-5, a 1,3,5-triazine derivative, has antimicrobial effects on E. coli 
RP437, P. aeruginosa PAO1 and PDO300 cells, with a minimum inhibitory concentration (MIC) 
of 12.8 µM, and kills regular planktonic cells of both species dose dependently. TN-5 was also 
 
 
found effective against persister and biofilm cells of both E. coli and P. aeruginosa; and 
the killing of biofilm cells of the mucoid PDO300 was enhanced by alginate lyase. 
To understand the effects of AMP charge on the killing effects, we modified the net charge of 
calcitermin originated from human airway secretions, and tested the effects on E. coli and P. 
aeruginosa planktonic and persister cells at different pH values. The neutral derivative of 
calcitermin showed better killing effect on persister cells at pH 7.4.  
Along with synthetic peptides, we also studied the membrane potential of persister cells with cell 
sorting and flow cytometry techniques using potentiometric dyes. Persister cells showed lower 
membrane potential along with lower efflux pump activities compared to normal cells. Based on 
these findings, we tested the hypothesis that persister cells can be effectively killed by antibiotics 
that are substrates of efflux pumps. Consistent with this hypothesis, erythromycin was 
found effective in killing persister cells of E. coli  while normal cells are resistant to it. This 
higher killing activity of erythromycin was corroborated with higher erythromycin accumulation 
in persister cells based on the results of Mass Spectrometry analysis.  
 
Key words: antibiotic tolerance, antibiotic resistance, antimicrobial peptides, membrane 
potential, persister cells, biofilm, killing, TN-5, 2D-24, Escherichia coli, Pseudomonas 
aeruginosa. 
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CHAPTER 1 
 
LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
A part of this chapter has been published as Ali Adem Bahar and Dacheng Ren. Antimicrobial 
Peptides. Pharmaceuticals 2013, 6: 1543-1575.  
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1.1 Current situation of antibiotic resistance and associated challenges 
Antibiotics have been used to treat infectious diseases for the last 70 years [1] with a great 
success in saving lives [2]. This achievement is considered as one of the most important 
breakthroughs in modern medicine [3]. However over-prescription and misuse of these drugs 
with unrestrained enthusiasm led to an unprecedented challenge to public health with the 
emergence of bacterial multidrug resistant strains [4]. Acquisition of antibiotic resistance is 
greatly aided by promiscuous transfer of conjugative plasmids, transposable elements and 
integron systems, among bacterial cells that are not necessarily related [5,6].  
Antibiotic resistance has been recognized as a global threat in 2013 by Centers for Disease 
Control [7] and several strains are listed as primary targets of new therapeutics including P. 
aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA). Infections caused by 
multidrug resistant bacteria are commonly associated with high mortality and health care costs 
[8] with 2 million people infected 23,000 and deaths annually in the U.S. alone [9], costing $20 
billion to the healthcare system according to Infectious Disease Society of America [10]. 
Moreover, antibiotic-resistant infections cost $35 billion indirectly due to societal impacts. On 
average, each hospitalized patient with antibiotic resistant infection costs around $24,000 along 
with two times higher mortality rate than regular patients [8].  
In addition to the increasing rate of the bacterial resistance, the number of bacterial species with 
antibiotic resistance has also been increasing. For example, the mortal sepsis rate caused by 
MRSA was 4% in the U.K. 1991; while this ratio increased to 37% in 1999 [11]. In a study by 
Kelman et al. in 2011, 69% of S. aureus isolates from meat products showed resistance to 
tetracycline and only 23% of the total isolates were found to susceptible to tetracycline, 
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penicillin, ampicillin, methicillin, erythromycin, clindamycin, gentamicin, chloramphenicol, 
oxacillin, cefoxitin, and quinupristin-dalfopristin antibiotics [12]. Another bacterial species 
causing serious infections is the opportunistic pathogen Pseudomonas aeruginosa. This 
bacterium can rapidly develop resistance to several classes of antibiotics through mobile genetic 
elements.  In some cases, this bacterium was found to even develop resistance during antibiotic 
treatment of an infection [13].  
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, 
Pseudomonas aeruginosa and Enterobacter, have been collectively named “the ESKAPE bugs” 
since they have remarkable capabilities to resist antibiotics and cause lethal infections [14]. 
Alarmingly, some infections are even resistant to all antibiotics that are currently available [15].  
In this research, we focused on two intrinsic mechanisms of antibiotic resistance; biofilm 
formation and persistence. This rapid and alarming increase in antibiotic resistant infections and 
the slowing pace of new antibiotic development [16] emphasize the needs for novel alternative 
therapeutic agents to cure infectious diseases especially those caused by multidrug-resistant 
(MDR) bacteria.  
Biofilms are multicellular structures of bacteria embedded in an extracellular polymeric 
substance (EPS) matrix [17]; and persister cells are metabolically inactive dormant phenotypic 
variants of bacterial cells that are highly tolerant to essentially all antibiotics [18]. These intrinsic 
tolerance mechanisms play major roles in the recalcitrance of chronic infections, such as the lung 
infections in cystic fibrosis patients [19]. 
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1.2 Mechanisms of antibiotic; acquired vs. intrinsic 
1.2.1 Acquired resistance 
Acquired resistance is based on genetic elements that allow bacteria to survive the attack by a 
specific antibiotic and closely related agents [7,20]. Bacteria can acquire specific resistance 
genes via transformation (uptake of extracellular DNA elements), transduction (through viruses 
or phages) conjugation (horizontal gene transfer from another bacteria) or genetic mutation 
during growth [21].  
The products of these genetic elements cause antibiotic resistance by degrading antibiotics, 
modifying the drug targets or quickly removing them from the cytosol. For example β-lactam 
antibiotics, such as penicillins are cleaved by β-lactamases in P. aeruginosa [22]. The 
widespread use of β-lactam antibiotics has caused the widespread of this gene among other 
bacteria such as K. pneumoniae, Salmonella spp. and P. mirabilis.  
 
1.2.2 Intrinsic tolerance 
 
Compared to acquired mechanisms that are against specific antibiotics, intrinsic mechanisms 
allow cells to tolerate a wide spectrum of different antimicrobials. Here we review three major 
examples; drug efflux, biofilm formation and persistence.  
 
1.2.2.1 Bacterial transport proteins: efflux pumps and porins 
 
Bacterial efflux pumps are substrate-specific protein transporters, which are located in the 
membrane and responsible for moving certain type of compounds, such as toxic metabolites and 
antibiotics, out of the cell [23]. These pumps are found in both Gram-negative and Gram-positive 
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bacteria and they can extrude virtually all clinically relevant antibiotics from cytosol to the 
external environment [24]. Efflux pumps require energy in the form of either ATP (originated 
from proton motive force) or ion gradient (Na+ or H+) across the cell membrane to extrude 
antibiotics [25].   
There are five known classes of efflux pumps in Gram-negative bacteria [26] (Fig. 1.1): ATP-
binding cassette family (ABC), multi antimicrobial extrusion protein family (MATE), small 
multidrug resistance family (SMR), resistance-nodulation-division (RND) family, and major 
facilitator superfamily (MFS) [26]. For example, 7 different efflux pumps have been identified in 
P. aeruginosa for transporting tetracycline, β-lactam, fluoroquinolones antibiotics, metal ions 
[27], small acylated homoserine lactones molecules [28], and quinolone signals [29]. 
 
Figure 1-1. Schematic representation of membrane transport proteins causing antibiotic 
resistance. (A); porins, (B); ATP-binding cassette family and multidrug (ABC) family, (C); multi 
antimicrobial extrusion protein (MATE) family, (D); small multidrug resistance (SMR) family 
and major facilitator superfamily (MFS), (E); resistance-nodulation-division (RND) family.  
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The other type of transport proteins related to antimicrobial resistance is porin proteins mainly 
present in the outer membrane of Gram-negative bacteria. Porins play an important role in the 
semi-permeability of the membrane with unique channels for transporting small and charged 
molecules. These cylindrical shaped tubes are composed of β-strands while polar residues face 
inward into the aqueous channel and nonpolar residues face outward to interact with nonpolar 
lipid membrane [30].  
 
1.2.2.2 Biofilm and persister formation  
 
Biofilms are complex multicellular structures of bacteria [31] which protect bacteria against 
antimicrobial therapies and adverse environmental conditions. Extracellular DNA, 
polysaccharides, and fatty acids are some of the major components of the biofilm matrix 
macromolecules, which help to maintain the biofilm structure and facilitate the development of 
biofilm [32]. During biofilm formation, free swimming bacterial cells attach to a surface 
reversibly and form small cell clusters first. These small cell clusters then secrete 
polysaccharides and form the mature biofilm structure with large cell aggregates and water 
channels between cell clusters.  
The multicellular biofilm structure protects bacterial cells from antimicrobials, immune factors 
and environmental toxins. For example, these biofilm cells exhibit up to 1000 higher tolerance to 
antibiotics compared to normal planktonic cells [33]; and biofilms are associated with more than 
80% of human infections [34] with high mortality [35] such as cystic fibrosis [36].  
In addition to the multicellular structure, biofilms also host a large number of persister cells 
which are phenotypic variants with inactive metabolism and thus high tolerance to antimicrobials 
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[37]. Persister cells are a small group of cells with no extra genetic modification for drug 
resistance [19]. Unbalanced toxins/anti-toxins production [38-41] and stress response and 
translation inhibition are known characteristics of persister cells [19,42]. These small group of 
cells can survive through the antibiotic course and form the normal population with similar 
percentage of persister cells again when the conditions turns back to normal for bacterial survival 
[43]. This repopulation ability provides higher level of antibiotic tolerance and chance to develop 
acquired resistance for bacterial cells [43]. Therefore, targeting persister cells will help for a 
better treatment of chronic infections caused by multidrug resistant bacteria [44].  
Because of the essential functions of cell membranes, antimicrobial agents targeting cell 
membranes have good potential for persister controls. One class of such agents is antimicrobial 
peptides (AMP). AMPs are oligopeptides with a varying number (from five to over a hundred) of 
amino acids with a broad spectrum of targeted organisms ranging from viruses to parasites. Most 
of the AMPs are membrane-active agents, which are positively charged, and act on negatively 
charged phospholipid bilayer of bacterial membrane [45] where main energy synthesis and many 
other important function occurs. It has been reported that some AMPs can sensitize bacteria by 
depolarizing the membrane at sub-lethal concentrations [46] and resistance against such 
antibacterial agents is difficult to acquire [47].  
 
1.3 Antimicrobial peptides 
 
Due to rapid development of bacterial resistance to conventional antibiotics, antimicrobial 
peptides (AMPs), have received increasing attention as an alternative way of fighting against 
antibiotic resistance. AMPs are a growing class of natural and synthetic peptides with a wide 
spectrum of targets including viruses, bacteria, fungi, and parasites. In this section, we 
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summarize the major types of AMPs, their modes of action, and the common mechanisms of 
AMP resistance. In addition, we discuss the principles for designing effective AMPs and the 
potential of using AMPs to control biofilms and persister cells.  
 
1.3.1 Sources and history of antimicrobial peptides  
 
Historically AMPs have also been referred to as cationic host defense peptides [48], anionic 
antimicrobial peptides/proteins [49], cationic amphipathic peptides [50], cationic AMPs [51], 
host defense peptides [52], and α-helical antimicrobial peptides [53]. 
The discovery of AMPs dates back to 1939, when Dubos [54-55] extracted an antimicrobial 
agent from a soil Bacillus strain. This extract was demonstrated to protect mice from 
pneumococcal infection. In the following year, Hotchkiss and Dubos [56] fractionated this 
extract and identified an AMP which was named gramicidin. Despite some reported toxicity 
associated with intraperitoneal application [56], gramicidin was found effective for topical 
treatment of wounds and ulcers [57]. In 1941, another AMP, tyrocidine, was discovered and 
found to be effective against both Gram-negative and Gram-positive bacteria [58]. However, 
tyrocidine exhibited toxicity to human blood cells [59]. In the same year, another AMP was 
isolated from a plant Triticumaestivum [60], which was later named purothionin and found 
effective against fungi and some pathogenic bacteria [61]. 
The first reported animal-originated AMP is defensin, which was isolated from rabbit leukocytes 
in 1956 [62]. In the following years, bombinin from epithelia [63] and lactoferrin from cow milk 
[64] were both described. During the same time, it was also proven that human leukocytes 
contain AMPs in their lysosomes [65]. 
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In total, more than 5,000 AMPs have been discovered or synthesized up to date [66]. Natural 
AMPs can be found in both prokaryotes (e.g., bacteria) and eukaryotes (e.g., protozoan, fungi, 
plants, insects, and animals) [67, 68-70]. In animals, AMPs are mostly found in the tissues and 
organs that are exposed to airborne pathogens; and are believed to be the first line of the innate 
immune defense [71,72] against viruses, bacteria, and fungi [68]. Thus, AMPs play an important 
role in stopping most infections before they cause any symptoms. For example, frog skin is the 
source of more than 300 different AMPs [67,73]. Most AMPs are produced by specific cells at all 
times, while the production of some AMPs is inducible. For example, using silk moth as a model 
system, Hultmark and colleagues [74] demonstrated that P9A and P9B can be induced in 
hemolymph by vaccination with Enterobacter cloacae. In another study [75], epithelial cells 
from different tissues of mice showed increased rate of mRNA transcription for defensin 
production after infection with Pseudomonas aeruginosa PAO1. 
Several types of eukaryotic cells are involved in AMP production such as lymphs, epithelial cells 
in gastrointestinal and genitourinary systems [76,77], phagocytes [78], and lymphocytes of the 
immune system [68,79]. In addition to direct involvement in innate immunity, AMPs have also 
been found to influence host’s inflammatory responses during an infection [80-82]. It is known 
that lipopolysaccharide (LPS) molecules, released from bacteria as a result of antibiotic 
treatment or host immunity, can induce AMP production in mammals [78]. For example, 
HEK293 cells produce defensin in response to LPS stimulation [83]. Some AMPs (e.g., CAP18 
[84], CAP35 [85], and a lactoferrin-derivative [86]) can also block LPS-induced cytokine release 
by macrophages. Thus, these AMPs can reduce inflammatory response. In comparison, 
antibiotics do not have this type of regulation on inflammatory response of the host immune 
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system; and LPS secretion following antibiotic treatment might cause over-reaction of the host 
immune system. In some extreme cases, this can even lead to sepsis [78,87]. 
 
1.3.2 Structure and major activities of AMPs  
Most AMPs reported to date can be characterized as one of the following four types based on 
their secondary structures: β-sheet, α-helix, extended, and loop. Among these structural groups, 
α-helix and β-sheet structures are more common [88]; and α-helical peptides are the most studied 
AMPs to date. In α-helix structures the distance between two adjacent amino acids is around 0.15 
nm and the angle between them with regard to the center is around 100 degree from the top view 
(Fig. 1-2A). The best known examples of such AMPs are protegrin, magainin, cyclic indolicin, 
and coiled indolicin [53]. β-sheet peptides are composed of at least two β-strands with disulfide 
bonds between these strands [89]. 
 
Figure 1-2. Schematic representation of an α-helical AMP. This figure assumes the same α-helix 
propensity for all amino acids in the peptide structure. (A) Helical wheel projection of the AMP 
(top view). The angle between two consecutive amino acids in the sequence is 100 degree. 
Dotted lines show two adjacent amino acids in the primary structure. (B) Side view of the 
peptide. The distance between two adjacent amino acids, “n”, is 0.15 nm. 
 11 
 
Some AMPs do not belong to any of these groups [90]. Some AMPs contain two different 
structural components [91]. Also, many peptides form their active structure only when they 
interact with the membranes of target cells. For example, indolicin shows globular and 
amphipathic conformation in aqueous solutions, while it is wedge-shaped in lipid bilayer 
mimicking environments [92]. This AMP also changes its conformation during interaction with 
DNA evidenced with decreased fluorescence intensity and a slight shift in the wavelength of 
maximum emission [93]. 
Unlikely antibiotics, which target specific cellular activities (e.g., synthesis of DNA, protein, or 
cell wall), AMPs target the lipopolysaccharide layer of cell membrane, which is ubiquitous in 
microorganisms. Having a high level of cholesterol and low anionic charge puts eukaryotic cells 
out of the target range of many AMPs [94]. 
Another important feature of AMPs is their rapid killing effect. Some AMPs can kill in seconds 
after the initial contact with cell membrane [95]. AMPs are also known to enhance the activities 
of antibiotics through synergistic effects. For example, the combination of penicillin with 
pediocin and ampicillin with nisin Z exhibited killing of Pseudomonas fluorescens with 13- and 
155-fold lower minimum inhibitory concentration (MIC), respectively, compared to using 
antibiotics alone [96]. 
Because AMPs are made with amino acids, it is relatively easy to modify the structure (including 
library construction and screening) and immobilize AMPs on surfaces [97]. It is possible to make 
fully synthetic peptides by chemical synthesis [98] or by using recombinant expression systems 
[99,100]. These artificial sources of AMPs are useful for modification of existing AMPs and for 
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designing new synthetic AMPs. Such modifications have potential to change the targets of AMPs 
and improve the stability of AMPs against proteases [101]. 
Despite these advantageous features of AMPs, there are still some challenges to their 
applications, such as potential toxicity to humans [59,102,103], sensitivity to harsh 
environmental conditions (susceptibility to proteases and extreme pH [104,105]), lack of 
selectivity against specific strains [106], high production costs [107], folding issues of some 
large AMPs [108], reduced activity when used for surface coating [109], and bacterial resistance 
to some AMPs [110,111]. In the following section we will discuss the modes of actions of AMPs 
and the current efforts to address the above challenges. 
 
1.3.3 Major categories of AMPs and mechanisms of action 
 
1.3.3.1 Classification 
 
In general, enzymatic mechanisms are not involved in the antimicrobial activities of AMPs 
[112]. For example, even though lysozyme is a monomeric peptide, it is not classified as an 
AMP because it is relatively large (148 aa) and kills bacteria through enzymatic activities by 
breaking 1,4-β-linkages in peptidoglycan chains [113]. Here, we categorize AMPs based on their 
target and mode of action. For natural AMPs, we will focus on those from eukaryotes, especially 
mammals. 
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1.3.3.1.1 Antiviral peptides 
Antiviral AMPs neutralize viruses by integrating in either the viral envelope or the host cell 
membrane. Previous studies have shown that both enveloped RNA and DNA viruses can be 
targeted by antiviral AMPs [114,115]. AMPs can integrate into viral envelopes and cause 
membrane instability, rendering the viruses unable to infect host cells [116,117]. AMPs can also 
reduce the binding of viruses to host cells [118]. For example, defensins bind to the viral 
glycoproteins making herpes simplex viruses (HSV) unable to bind to the surface of host cells 
[119]. 
Besides disruption of viral envelopes and blocking viral receptors, some antiviral AMPs can 
prevent viral particles from entering host cells by occupying specific receptors on mammalian 
cells [120,121]. For example, heparan sulfate is important for the attachment of HSV viral 
particles to the host cell surface [122]. The heparan sulfate molecules are negatively charged 
glycosaminoglycan molecules [123]. Thus, some α-helical cationic peptides, e.g., lactoferrin 
[124], can prevent HSV infections by binding to heparan molecules and blocking virus-receptor 
interactions [125]. 
Compared to the above AMPs that target viral receptors on cell surface, some AMPs do not 
compete with viral glycoproteins for binding to the heparansulphate receptors on cell surface. 
Instead, these antiviral AMPs can cross the cell membrane and localize in the cytoplasm and 
organelles, causing changes in the gene expression profile of the host cells, which can help the 
host defense system fight against viruses or block viral gene expression. For example, NP-1, an 
AMP from rabbit neutrophils, prevents Vero and CaSki cell lines from infection by herpes 
simplex viruses type 2 (HSV-2). This AMP stops the viruses by preventing the migration of a 
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major viral protein, VP16, into the nucleus. This viral protein is required to form complexes with 
the host transcriptional factors to induce the expression of immediate early viral genes, which are 
required for the virus to defeat the first stage cellular response [126]. Thus, this AMP does not 
compete with viral particles to bind to the receptor on cell surface but it prevents cell-to-cell 
spread of viral particles [127]. 
 
1.3.3.1.2 Antibacterial peptides 
Antibacterial AMPs are the most studied AMPs to date and most of them are cationic AMPs, 
which target bacterial cell membranes and cause disintegration of the lipid bilayer structure 
[128,129]. The majority of these AMPs are also amphipathic with both hydrophilic and 
hydrophobic domains. Such structures provide AMPs the capability to bind to lipid components 
(hydrophobic region) and phospholipid groups (hydrophilic region) [94]. 
Interestingly, researchers have demonstrated that some AMPs at low concentrations can kill 
bacteria without changing the membrane integrity. Instead of directly interacting with the 
membrane, these AMPs kill bacteria by inhibiting some important pathways inside the cell such 
as DNA replication and protein synthesis [130]. For example, buforin II can diffuse into cells 
and bind to DNA and RNA without damaging the cell membrane [131]. Drosocin, pyrrhocoricin, 
and apidaecin are other examples of such AMPs. These AMPs have 18–20 amino acid residues 
with an active site for their intracellular target [132,133]. 
In some cases, certain AMPs have been shown to kill antibiotic resistant bacteria. For example, 
both nisin (an AMP) and vancomycin (an antibiotic), can block cell wall synthesis. However, a 
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methicillin resistant Staphylococcus aureus (MRSA) strain was reported to be resistant to 
vancomycin, while it is still sensitive to nisin [134]. 
 
1.3.3.1.3 Antifungal peptides 
Like antibacterial AMPs, antifungal peptides can kill fungi by targeting either the cell wall 
[135,136] or intracellular components [137]. However, bacterial membrane and fungi cell wall 
have different contents. For example, chitin is one of the major components of fungal cell walls 
and some of antifungal peptides are capable of binding to chitin [138-140]. Such binding ability 
helps AMPs to target fungal cells efficiently. Cell wall targeting-antifungal AMPs kill the target 
cells by disrupting the integrity of fungal membranes [141,142], by increasing permeabilization 
of the plasma membrane [143], or by forming pores directly [144]. 
Although the majority of antifungal AMPs have polar and neutral amino acids in their structures, 
[94] there does not appear to be a clear correlation between the structure of an AMP and the type 
of cells that it targets. For example, antifungal peptides have members from different structure 
classes such as α-helical (D-V13K [145] and P18 [146]), extended (indolicin [147]), and β-sheet 
(defensins [148]). 
 
1.3.3.1.4 Antiparasitic peptides 
Antiparasitic peptides are a smaller group compared to other three AMP classes. The first 
antiparasitic peptide reported is magainin, which is able to kill Paramecium caudatum [149]. 
Later, a synthetic peptide was developed against Leishmania parasite [150]. Another example of 
antiparasitic peptide is cathelicidin, which is able to kill Caernohabditis elegans by forming 
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pores in the cell membrane [151]. Even though some parasitic microorganisms are multicellular, 
the mode of action of antiparasitic peptides is the same as other AMPs. They kill cells by directly 
interacting with cell membrane [151]. 
 
1.3.3.2 Mechanism of action 
 
As described above, AMPs kill cells by disrupting membrane integrity (via interaction with 
negatively charged cell membrane), by inhibiting proteins, DNA and RNA synthesis, or by 
interacting with certain intracellular targets. All AMPs known by the late-90s are cationic. 
However, the concept that AMPs need to be cationic was changed later with the discovery of 
negatively charged AMPs in 1997 [152]. For example maximin-H5 [153] from frog skin and 
dermicidin [154] secreted from sweat gland tissues of human are both anionic peptides. 
Generally an AMP is only effective against one class of microorganisms (e.g., bacteria or fungi) 
[78]. However, there are exceptions and some AMPs are known to have different modes of 
action against different types of microorganisms. For example, indolicidin can kill bacteria, 
fungi, and HIV [116,155]. It exhibits antifungal activities by causing damages to cell membrane 
[147]. However, it kills E. coli by penetrating into the cells and inhibiting DNA synthesis [156]; 
and it shows anti-HIV activities by inhibiting HIV-integrase [157]. In comparison; some AMPs 
have the same mode of killing of different cell types. For example, PMAP-23 can kill both fungi 
and parasites by forming pores in their cell membranes [151,158]. 
One third of the total proteins of a bacterial cell are associated with the membrane and these 
proteins have many functions that are critical to the cell including active transport of nutrients, 
respiration, proton motive force, ATP generation, and intercellular communication [159]. The 
 17 
 
function of these proteins can be altered with AMP treatment even if complete cell lysis does not 
occur. Therefore, AMPs’ rapid killing effect does not only come from membrane disruption but 
can also come from inhibition of these functional proteins. 
 
1.3.3.2.1 Membrane-active AMPs 
 
Even if intracellular targets are involved, an initial cell membrane interaction with peptides is 
required for the antimicrobial activities of AMPs [160]; and this interaction determines the 
spectrum of target cells. Most membrane-active AMPs are amphipathic, which means that they 
have both cationic and hydrophobic faces. This feature ensures the initial electrostatic interaction 
with the negatively charged cell membrane and the insertion into membrane interior. The actions 
of AMPs do not stop after this initial interaction. The hydrophobic part of an AMP helps insert 
the AMP molecule into the cell membrane [161]. So the interaction mainly includes ionic and 
hydrophobic interactions. These interactions mostly depend on two properties, e.g., cationic state 
and hydrophobicity of the peptide. The major types of membrane-active AMPs and the 
mechanisms of their actions are summarized in Table 1-1 and Figure 1-3. 
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Table 1-1. The action mechanisms of membrane-active AMPs. 
Interaction 
model Mechanism References 
Carpet like 
(Detergent-like) 
The peptide micelle touches the membrane first and coats 
a small area of the membrane. Then AMP molecules 
penetrate the lipid bilayer to let pore formation leaving 
holes behind. 
[162-164] 
Membrane 
thinning 
AMPs insert themselves into only one side of the lipid 
bilayer. It can form a gap between lipid molecules at the 
chain region. This gap creates a force and pulls the 
neighboring lipid molecules to fill it. 
[165-167] 
Aggregate 
AMPs stick to the membrane parallel to the surface. 
Then reorientation of AMPs occurs and they insert 
themselves into the membrane vertically to form sphere-
like structures. 
[162,168-
170] 
Toroidal pore 
AMPs align perpendicularly into the bilayer structure 
with their hydrophobic regions associated with the center 
part of the lipid bilayer and their hydrophilic regions 
facing the pore. 
[130,170] 
Barrel-stave 
Staves are formed first parallel to the cell membrane. 
Then barrels are formed and AMPs are inserted 
perpendicularly to the plane of the membrane bilayer. 
[129,171,172] 
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Figure 1-3. Schematic representation of some action mechanisms of membrane-active AMPs. (A) 
Barrel-Stave model. AMP molecules insert themselves into the membrane perpendicularly. (B) 
Carpet model. Small areas of the membrane are coated with AMP molecules with hydrophobic 
sides facing inward leaving pores behind in the membrane. (C) Toroidal pore model. This model 
resembles the Barrel-stave model, but AMPs are always in contact with phospholipid head 
groups of the membrane. The blue color represents the hydrophobic portions of AMPs, while the 
red color represents the hydrophilic parts of the AMPs. 
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1.3.3.2.2 Intracellularly active AMPs 
 
In early AMP studies, permeabilization of bacterial cell membrane by AMP was thought as the 
primary mechanism of killing. It was suggested that AMPs should be used at concentrations high 
enough so that they can kill microorganisms by disrupting the membrane with sufficient 
channels and pores [173]. However, some AMPs were found to start membrane permeabilization 
at concentrations lower than their MICs, while others could only do so at concentrations higher 
than their MICs. The finding that some AMPs can kill their target cells without causing 
membrane permeabilization suggests that there may be other mechanisms of killing. Recently, 
intracellularly active AMPs have been shown to interact with targets inside the cells [174-176]. 
For example indolicin was shown to bind to DNA with a preferred sequence [93,177]. 
Some AMPs can inhibit DNA and protein synthesis [178,179]. One example of this is PR-39, an 
AMP from pig intestines, which kills bacteria in a non-lytic process by acting like a proteolytic 
agent and stopping protein and DNA synthesis [180]. Similar to PR-39, indolicin does not lyse 
cells directly. It enters the cytoplasm and kills bacterial cells by targeting DNA synthesis [156] 
[178]. Also, some human immune system derived AMPs such as tPMP-1 and aHNP-1 inhibit 
DNA and protein synthesis within an hour after they enter the cells [181]. Apidaecin is another 
protein synthesis blocking AMP which lacks pore forming ability. This AMP is only effective 
against Gram-negative bacteria. It is suggested that this AMP is actively transported with a 
transporter protein and then it blocks protein synthesis with a series of molecular interactions 
with different targets [182]. 
Some AMPs can also inhibit proteases of microbes. For example, histatin 5 stops the periodontal 
tissue destruction by inhibiting a protease from Bacteriocides gingivalis [183]; and eNAP-2 has 
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anti-protease activities against microbial serin proteases [184]. Interestingly, there are some 
intracellular AMPs which can only kill cells at certain growth stages. For example, diptericin is 
only effective against actively growing bacterial cells, suggesting it may interact with certain 
specific metabolic pathways during bacterial growth [185,186]. 
Among these intracellularly active AMPs, some of them have multiple targets. For example 
seminalplasmin inhibits RNA polymerase and can stop RNA synthesis completely at 
concentrations lower than many other antibacterial agents [187]. On the other hand, the same 
AMP can activate an autolysin protein inside the target cells leading to autolysis [188,189]. 
Inhibition of intracellular pathways by AMPs [173,178] suggests that there might be mechanisms 
of cellular uptake of AMPs. Two such mechanisms have been reported: direct penetration and 
endocystosis [161]. According to Jones [190], cellular uptake of AMPs can take place through 
endocytosis, which includes macropinocytosis and receptor mediated endocytosis. In 
macropinocytosis, the cell membrane folds inward and forms vesicles with the help of dynamin 
proteins. These vesicles are called macropinosomes and they are like small cells with only a 
membrane around them [161]. In receptor mediated endocytosis, a part of the membrane is 
coated with clathrin or caveolin proteins followed by pit formation. Later, these pits bud from the 
membrane to inner side of the cell and form vesicles [190,191]. 
 
1.3.4 Designing new synthetic AMPs: major factors to consider  
 
To date, no data have been reported to demonstrate a clear relationship between the structural 
groups of an AMP and its mode of action, the degree of activity, or the host range. Even the 
AMPs with very similar structures can have drastically different mechanisms of action and the 
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range of targeted cells [94]. For example, buforin targets DNA and RNA; while magainin 2, an 
AMP with similar structure, targets the cell membrane causing cell lysis [192,193]. Although a 
structure-based precise prediction of activity, mode of action, and host range may not be 
possible, certain general design principles have been proposed by previous studies. The AMP 
structure is certainly important, while the size, charge, hydrophobicity, amphipathicity, and 
solubility are all crucial physiochemical properties for their antimicrobial activities and target 
specificity of AMPs [194]. Changing these features will help to modify the activity and target 
spectrum of AMPs. 
 
1.3.4.1 Important physiochemical properties of AMPs 
 
1.3.4.1.1 Length  
 
The length of an AMP is important to its activity because at least 7–8 amino acids are needed to 
form amphipathic structures with hydrophobic and hydrophilic faces on opposite sides of a 
peptide molecule. The size for an AMP to transverse the lipid bilayer of bacteria in the barrel-
stave model should be at least 22 amino acids for α-helical AMPs, while eight amino acids are 
needed for β-sheet AMPs [195]. Besides the effects of length on its 3D structure and mode of 
action, the length of an AMP may also affect its cytotoxicity. For example, a shortened melittin 
with 15 residues at its C-terminal [196] and a shorter derivative of HP(2-20) [197] exhibited at 
least 300 times less toxicity to rat erythrocytes and human erythrocytes, respectively, compared 
to their original forms. Therefore, the length of AMP should be taken into consideration when 
designing new synthetic peptides with low toxicity. 
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1.3.4.1.2 Net charge 
 
The net charge of known AMPs, which is the sum of all charges of ionizable groups of the 
peptide, varies from negative to positive and it is the main factor for the initial interaction with 
negatively charged cell membranes. By changing the net charge of an AMP, its antimicrobial and 
hemolytic activities can be altered to achieve selective killing of microbes with no or minimized 
effects on host cells. For example, increasing positive net charge of V13K from +8 to +9 resulted 
in higher hemolytic activity, while decreasing the net charge to lower than +4 abolished its 
activity against P. aeruginosa [145]. 
 
1.3.4.1.3 Helicity 
 
Helicity represents the ability of an AMP to form spin structure. It is less important for the 
activity of an AMP compared to other factors discussed above. However, it is important for 
determining the toxicity on eukaryotic cells [53]. Reducing helicity by incorporating D-amino 
acids into the primary sequence has been shown to lower the hemolytic effect, while the 
antimicrobial effect was retained [198]. For example, Papo et al. [101] modified some α-helical 
peptides by replacing 35% of the L-amino acids with D-amino acids and found that this 
modification eliminated the hemolytic activity. Besides, these new synthetic AMPs are not 
sensitive to proteases. Therefore, incorporating D-amino acids to change helicity is a useful 
strategy for designing new synthetic peptides with less hemolytic activity and enhanced stability 
against proteolytic cleavage. Another important factor associated with the helicity of AMP is the 
helix propensity of each amino acid in the primary sequence. For example, proline and glycine 
have lower helix-forming propensities compared to other amino acids [199]. Thus, these residues 
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are not preferred when designing α-helical AMPs. In addition, peptides should be flexible 
enough to change their conformation during the membrane insertion process [94]. 
 
1.3.4.1.4 Hydrophobicity 
 
Hydrophobicity has also been shown to influence the activity and selectivity of AMP molecules. 
Almost 50% of amino acids in the primary sequence of natural AMPs are hydrophobic residues 
[194]. In most cases, increase in hydrophobicity on the positively charged side of an AMP below 
a threshold can increase its antimicrobial activity [53], while decreasing hydrophobicity can 
reduce antimicrobial activity [200]. There appears to be an optimal hydrophobicity for each 
AMP, beyond which its activity decreases rapidly [176]. Therefore, when designing new 
synthetic peptides, the hydrophobicity should be selected within an optimal window. Some 
previous studies have shown that hydrophobicity is also critical for determining the range of 
target cells of an AMP. Increasing the hydrophobicity of an AMP can change the range of targets 
[201,202]. For example, magainin is an AMP that is only effective against Gram-negative 
bacteria. However, some synthetic analogs with higher hydrophobicity can also kill some Gram-
positive bacteria and eukaryotic cells [203]. 
 
1.3.4.1.5 Amphipathicity 
 
Amphipathicity is another important property of AMPs to ensure their activity and interaction 
with microbial membranes. Fernandes-Vidal et al. [204] showed that amphipathicity is more 
important than hydrophobicity for binding to microbial membranes. Because amphipathicity of 
AMPs is required for a strong partition into the membrane interface, priority should be given to 
the amphipathic structure when designing synthetic AMPs for specific target cells. 
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1.3.4.1.6 Solubility 
 
Since AMPs should act on or enter through lipid membranes, they need to be soluble in aqueous 
environments. If AMP molecules aggregate, it will lose its ability to interact with the cell 
membrane. For example, a hybrid synthetic AMP composed of cecropin and melittin has a 
tendency to form dimers. Substituting a Lys (L) residue on the non-polar face of this hybrid 
AMP prevents dimerization and leads to reduced hemolytic activity. Losing dimerization ability 
makes this AMP more effective for its incorporation into microbial membranes [205]. This 
example demonstrates the importance of solubility and the value of structural optimization. 
 
1.3.4.2 The relationship between physiochemical properties of AMPs 
 
As discussed above, many factors affect the activities of AMPs and some interactions exist 
between these factors. In AMP design, these properties need to be considered together since 
changing one of these parameters to get a desired modification of an AMP may alter other 
parameters. Even a simple change in primary sequence can affect many other physicochemical 
parameters which are often vital for the activity of an AMP and the range of target cells [206]. 
Predicting the results of an AMP modification or the function of a synthetic peptide beforehand 
is still an unmet challenge. Application of molecular simulation to analyze the details of the 
folding of AMP molecules and interaction with target cells [207,208] may be a promising 
approach to improve current trial and error methods. 
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1.3.4.3 AMP modifications 
 
While most of AMPs are directly synthesized in their active forms, post-translational 
modification of certain AMPs is necessary for their functions. Naturally forming AMPs are 
processed with different post-translational modifications such as phosphorylation [209], addition 
of D-amino acids [210,211], methylation [212], amidation [213], glycosylation [214], formation 
of disulphide linkage [215], and proteolytic cleavage [71,216]. In some cases, these 
posttranslational modifications might be important for designing new synthetic AMPs. Even 
though recombinant cell systems can be used to produce these synthetic peptides with post-
translational modifications, incorporation of unnatural amino acids may require chemical 
synthesis [107]. 
 
1.3.4.3.1 Modification of AMPs with covalent bonds 
 
Covalent modification can have profound effects on the structure and function of an AMP. Even 
a single disulfide bond can change the antimicrobial effect of an AMP. For example, protegrin 
missing a disulphide bond becomes inactive against HSV [217]; while adding disulphide bond in 
sakacin P resulted in higher antimicrobial activities [91]. In another study, a disulfide bond was 
added in CP-11, a derivative of indolicidin [218], and a Trp-Trp cross-link was added in 
indolicin [219]. These modified structures of indolicidins showed higher protease stability with 
no change in antimicrobial activity. However increase in stability does not always lead to better 
AMPs. For example, Houston et al. [220] introduced a covalent bond to form a lactam bridge 
between Gln (G) and Lys (L) residues in two α-helical AMPs, e.g., cecropin and mellitin. This 
modification helped AMPs to form more stable α-helix structures but decreased the antimicrobial 
activity of both. 
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1.3.4.3.2 Modification of AMPs by changing amino acid content 
 
Alteration of amino acid content is one of the most studied strategies of AMP modification. Most 
of these studies focus on certain amino acids since their physiological characteristics play 
important roles in the activity and target spectrum of AMPs. For example proline content in the 
primary sequence of an AMP has been found to affect its ability to penetrate cell membranes. 
Higher proline content reduces the capability of CP26 to permeabilize E. coli cell membrane 
[221]. This effect might be because of proline’s low propensity to form α-helical structures. Thus 
changes in the proline content may lead to alterations of α-helical posture of an AMP. 
Changing amino acid content can also affect cytotoxicity. In a study by Nell et al. [222], LL37, a 
human AMP, was modified by removing neutral amino acids Asn (A) and Gln (E), and adding 
more positively charged residues (two Arg (R) units) into the primary sequence. The new 
synthetic peptide showed less cytotoxic effects on eukaryotic cells. This peptide was named 
P60.4 and has been successfully used in nasal applications against MRSA [223]. Another 
strategy to improve AMP stability is to include D-amino acids in the sequence because they are 
more tolerant to proteases [224,225]. 
 
1.3.4.3.3 Modification of AMPs by amidation 
 
With new developments in peptide synthesis, it is possible to incorporate special chemical 
groups or unnatural molecules into AMPs. One of these modifications is the addition of amide 
groups at the end of the peptides. In 2011, Kim et al. [226] modified PMAP-23 with amidation at 
the carboxyl end and found that this derivative of PMAP-23 orients perpendicularly inside the 
bacterial membrane while original PMAP-23 orients parallel to the membrane. This modification 
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resulted in almost 10 fold higher cellular uptake, faster interaction with Gram-negative bacteria 
cell membrane, and deeper insertion into the inner membrane than the original PMAP-23. This 
carboxyl-end amidated synthetic peptide also showed better membrane-permeabilization in 
liposome release tests [226]. Therefore amidation of carboxyl end has good potential to improve 
the function of synthetic AMPs. 
C-terminal modifications can also affect the stability of AMPs. In a previous study by Berthold 
et al. [227], the C-terminal amide group of Api88 was replaced by a free acid. This modification 
did not change its antimicrobial activity, but resulted in a 15 times more stable Api88 derivative 
against proteases in blood serum. Replacing Arg-17 of this AMP with L-ornithine or L-
homoarginine gave 35 times higher proteolytic stability than the original Api88. However, the 
latter modification decreased the antimicrobial activity by eight fold [227]. 
 
1.3.4.3.4 Modification of AMPs with unnatural amino acids 
 
A number of studies on synthetic peptides have attempted to incorporate unnatural amino acids 
into the primary sequence [146,228,229]. β-didehydrophenylalanine is an unnatural amino acids 
and is used to provide better folding properties for AMPs [228]. It is widely used in medicinal 
chemistry to alter the native bioactive AMPs [230]. Incorporation of β-didehydrophenylalanine 
in the primary sequence of VS1 resulted in higher stability against proteases. Researchers have 
also been able to introduce antifungal activities to some AMPs by incorporating undecanoic acid 
and palmitic acid into their primary sequence [146,231]. 
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1.3.4.3.5 Modification of AMPs with computer-assisted methods 
 
The use of computer-assisted methods in AMP research has been increasing significantly [232-
237]. Estimating the structure of an AMP based on its primary sequence [238], then predicting 
potential mechanism of action and activity is becoming easier with the help of computational 
approaches [239]. These types of artificial AMP design strategies hold potential for developing 
new synthetic peptides against antibiotic-resistant superbugs [237]. Several databases about 
AMPs have been created and can be accessed to compare currently available AMPs. One of the 
latest AMP databases, LAMP (linking antimicrobial peptides), currently has 3904 natural and 
1643 synthetic peptides [66]. 
 
 
1.3.4.4 New AMP design by homology modeling 
 
Most studies about AMPs to date are inspired by natural AMPs. For example, Tossi et al. [240] 
designed some synthetic peptides by identifying the common amphipathic structure of 87 
different natural α-helical AMPs. These natural AMPs are composed mainly of cecropins, 
magainins, brevinins, and cathelicidin peptides sourced from insects, amphibian, and mammals. 
This synthetic peptide study focused on the first 20 amino acids in each sequence because the N-
terminal region was shown to be necessary for antimicrobial activities [241,242]. The synthetic 
peptides designed based on this strategy are able to transform into α-helical structures from 
random structures with the addition of trifluoroethanol in aqueous environments. These synthetic 
AMPs exhibited antimicrobial activities against Gram-positive and Gram-negative bacteria, 
including some drug resistant strains. In addition, these synthetic AMPs showed low toxicity to 
some eukaryotic cell lines [240]. 
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Designing synthetic AMPs by homology modeling within the same class might also provide a 
better understanding of activity-structure relationship. Important elements from the same AMP 
class may be identified using this approach to help design better molecules. Storici et al. [242] 
showed that 20 residues (named PMAP-36) of an antibacterial peptide from pig bone marrow 
cells are sufficient for related antibacterial activity. The AMP with these 20 residues was 
chemically synthesized and showed the capability to form α-helix in the presence of 
trifluoroethanol. This short synthetic peptide was found to induce permeabilization of the inner 
membrane of E. coli ML35 at concentrations lower than 50 µM; while even at 100 µM it did not 
cause any permeabilization to human erythrocytes [242]. In another study of homology 
modeling, arenicin, protegrin, and thanatin were used as templates to generate three synthetic 
peptides: AMP72, AMP126 and AMP2041. These new synthetic AMPs showed lower 
cytotoxicity compared to the original AMPs and exhibited dose dependent antimicrobial 
activities (0.17 to 10.12 μM) against Gram-negative bacteria [243]. 
It is also possible to broaden the target spectrum of an AMP by homology modeling. For 
example, normally lactoferrampins are not effective against E. coli O157. A conserved sequence, 
which corresponds to an α-helical region, among these AMPs was found, by aligning multiple 
sequences with ClustalW analysis. This common region was modified by inserting GKLI 
sequence into its primary sequence, and the new synthetic peptide showed activities against E. 
coli O157 with a more stable structure compared to other lactoferrampins [244]. 
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1.3.5 New targets of AMPs: biofilms, persister cells, and drug resistance bacteria  
 
Because AMPs can directly target bacterial cells, they have potential to control antibiotic tolerant 
cells. Here we review some recent work on biofilms and persister cells. Biofilms are immobile 
bacterial populations attached to surfaces such as human tissues and medical implants. Biofilm 
formation on implant surfaces is a serious problem since every year more than $3 billion is spent 
to treat implant-associated biofilm infections in the U.S. alone [245]. With cells protected by an 
extracellular matrix, biofilms are highly tolerant to antimicrobials [246] and are a major cause of 
chronic infections; e.g., approximately 80% of human bacterial infections are associated with 
biofilms [247]. In addition to the protection by the extracellular matrix [248], biofilm associated 
antibiotic resistance is also attributed to the slow growth of biofilm cells [249]. Even though 
some antibiotics have been shown to effectively penetrate biofilm matrix [250], they are not 
effective against these slowly growing cells, especially the dormant subpopulation known as 
persister cells [251-253]. Since most AMPs target cell membrane, they may be more effective 
against these dormant cells compared to antibiotics. 
 
1.3.5.1 Biofilm control 
 
The first obstacle of using AMPs against biofilms is the possible electrostatic interaction 
between cationic peptides and negatively charged biofilm matrix [254]. Such interactions may 
retard or prevent AMPs from reaching biofilm cells. Previous studies have investigated the 
effects of some AMPs on biofilm inhibition and killing of bacterial cells in established biofilms. 
The second type of study is especially important since treatment of mature biofilms is highly 
challenging [252]. In a study by Singh et al. [255], lactoferrin was found to block biofilm 
 32 
 
formation of P. aeruginosa at concentrations lower than those required to kill the planktonic 
cells. Also, LL-37, a human cathelicidin AMP, was shown to prevent P. aeruginosa biofilm 
formation at the concentration of 0.5 µg/mL, which is below its MIC (64 µg/mL). This AMP 
also showed activity against preformed (2-days old) P. aeruginosa biofilms; e.g., it reduced the 
biofilm thickness by 60% and destroyed microcolony structures of the treated biofilms [256]. In 
another study, a derivative of LL-37 was found effective against both Gram-positive and Gram-
negative bacteria. Despite its weak antimicrobial activity against planktonic cells, this AMP 
inhibited biofilm formation of P. aeruginosa, Burkholderia cenocepacia, and Listeria 
monocytogenes with more than 50% reduction in biofilm mass compared to untreated controls 
[257]. The same study showed that this inhibition is due to decrease in swarming and swimming 
motilities, increase in twitching motility, and repression of some biofilm genes. 
In addition to free AMPs, surface coating with AMPs has also been pursued since surface 
modifications with AMPs might help reduce device associated infections [258-261]. Many 
AMPs have been tested for their inhibitory effects on biofilm formation on implant surfaces. For 
example, Tet-20, a synthetic peptide (KRWRIRVRVIRKC), tethered on an implant surface 
exhibited broad antimicrobial activities both in vivo (rats) and in vitro. It is able to stop biofilm 
formation and appears to be non-toxic to eukaryotic cells [258]. In another study, histatin 5 and 
lactoferrin were used to coat Ti surfaces covered with an anchor peptide minTBP (RKLPDAP), 
which helps binding of AMP to Ti surfaces. The conjugates of both AMPs resulted in higher 
binding efficiency to Ti surfaces than AMPs alone and Porphyromonas gingivalis showed less 
ATP activity and reduced biofilm formation on coated surfaces [262]. 
In addition to naturally existing AMPs, some synthetic AMPs were also used to treat biofilms. A 
synthetic histatin analogue dhvar4 was tested against oral flora on hydroxyapatite disks and this 
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AMP reduced the number of viable biofilm cells by 1.5 log compared to the control [263]. 
MUC7, a native saliva AMP from humans, and its modified forms, MUC17 12-mer-L and 20-
mer, showed inhibitory effects on S. mutans biofilm formation [264]. In another study, a 
derivative of LL-37 which is an AMP from human innate immune system, cleared P. sinusitis 
biofilms in vivo (New Zealand rabbits). However, it also led to some toxicity and 
proinflammation in the sinuses [265]. 
As discussed above, the extracellular matrix of a biofilm is thought to form a diffusion barrier 
against certain AMPs [246]. It is known that this negatively charged barrier protects the cells 
inside from positively charged antimicrobial agents and the alginate in biofilm matrix can reduce 
the diffusion of antimicrobial agents [266]. Thus, it is important to obtain AMPs that can diffuse 
into biofilms and kill biofilm cells. Recently a synthetic peptide, (RW)4D dendrimer [267] was 
demonstrated to inhibit planktonic growth and biofilm formation of E. coli dose dependently. 
This AMP inhibited biofilm formation by 93.5% at 40 µM. This dendrimer did not detach 
preformed biofilms, but was able to kill most of the cells residing in mature biofilms dose 
dependently [268]. Later, (RW)n-NH2 based AMPs with different chain length (where n = 2, 3, 
and 4) were compared for their effects on E. coli RP437 biofilms. The chain length was found to 
be important to the activity of these peptides. Longer peptides, (RW)3-NH2 and (RW)4-NH2, 
showed significant inhibition of planktonic growth (36% reduction in growth rate) while a 
shorter peptides (RW)2-NH2 did not cause a clear inhibition at concentrations up to 200 µM. This 
length-activity relation was also found for biofilm inhibition. E. coli biofilm surface coverage 
and the viability of biofilm cells were reduced significantly by the longer peptides (95% 
inhibition of biofilm growth by 200 µM (RW)3-NH2 and 84.4% inhibition of biofilm growth by 
200 µM (RW)4-NH2). Preformed biofilms were also tested with these peptides. However, the 
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treatment of preformed biofilms with these peptides did not show the same length-activity 
relationship. Interestingly, 200 µM (RW)3-NH2 showed significant killing of biofilm cells while 
200 µM (RW)4-NH2 showed strong biofilm dispersion (91.5% reduction in biofilm surface 
coverage at 200 µM) with no apparent killing effect on biofilm cells. Although 200 µM (RW)4-
NH2 did not kill biofilm cells directly, the detached biofilm cells were killed by this peptide 
effectively [269]. 
AMPs have also been tested against the biofilms of drug resistant bacteria. In a study by Okuda 
et al. [270], nisin A and lacticin Q were tested against mature biofilms of a MRSA strain, S. 
aureus MR23. Nisin A at 40 µM was found to kill more than 95% biofilm cells while lacticin Q 
at 80 µM killed around 90% of the biofilm cells. In another study, GL13K derived from human 
parotid secretory protein (PSP) killed 99.9% of 24 hour biofilm cells of P. aeruginosa when it 
was added at 100 µg/mL for a two hour treatment [271]. 
NRC-16, a synthetic peptide, was tested against biofilm formation of three P. aeruginosa strains 
and compared with antibiotics such as ampicillin, chloramphenicol, and ciprofloxacin. NRC-16 
showed biofilm inhibition at 8 µg/mL, which is 64 fold less than the antibiotic concentrations 
required to kill these P. aeruginosa strains [272]. 
There are also some AMPs that can sensitize biofilm cells to other antimicrobial agents. For 
example, lactoferrin does not kill S. epidermidis or affect its growth. However treatment of S. 
epidermidis biofilms on contact lenses with lactoferrin and vancomycin together showed a 2 fold 
decrease in both MBC (minimal bactericidal concentration) and MIC of biofilm cells compared 
to the treatment with vancomycin alone [273]. 
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1.3.5.2 Persister control 
 
Persister cells can be found in almost any microbial populations [19]. However, membrane 
integrity is essential for the survival of bacteria irrespective of the metabolic stage of the cell and 
cell membrane is a major target of AMPs. Thus, AMPs may have good potential to kill persister 
cells. In a recent study, a synthetic cationic peptide, (RW)4-NH2, was found to kill more than 
99% of E. coli HM22 persister cells in planktonic culture. Besides, this synthetic peptide reduced 
the number of persister cells in mature biofilms by up to 98% at 40 µM. More interestingly, the 
combination of this peptide with oflaxacin (5 µg/mL) resulted in complete eradication of viable 
cells in E. coli HM22 biofilms including persister cells [274]. Thus, the combination of 
conventional antibiotics with AMPs may offer a synergy to control drug tolerant infections. 
 
1.3.6 Resistance to antimicrobial peptides 
 
There are mainly two different types of resistance mechanisms against AMPs: constitutive 
resistance and inducible resistance [275]. The inducible resistance mechanisms include substitution 
[276], modification [277], and acylation [278] of the membrane molecules, activation of some 
proteolytic enzymes [279] and efflux pumps [280], and modifications of intracellular targets [281]. 
The constitutive resistance mechanisms include electrostatic shielding [282], changes in 
membrane potential during different stages of cell growth [283], and biofilm formation [275]. 
These resistance mechanisms are illustrated in Figure 1-4. 
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Figure 1-4. Schematic representation of AMP resistance mechanisms. (A) Gram-positive 
bacteria resist AMPs via teichoic acid modification of LPS molecules and L-lysine modification 
of phospholipids. (B) Gram-negative bacteria resist AMPs by modifying LPS molecules with 
aminoarabinose or acylation of Lipid A unit of LPS molecules. (C) Bacteria express some 
positively charged proteins and integrate them in the membrane so positive charges repulse each 
other and bacteria can resist such AMPs. (D) Bacteria produce negatively charged proteins and 
secrete them into extracellular environment to bind and block AMPs. (E) The intracellular AMPs 
are extruded by efflux pumps. (F) The AMPs inside the cell are degraded by proteases. 
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For example the activity of some AMPs against S. aureus can be inhibited by adhesin molecules 
on the cell surface of this bacterium. These adhesin molecules are polymeric substances and stay 
on the cell surface after secretion [284]. Since adhesin is a positively charged polymer, it can 
form a repulsive barrier against positively charged AMPs. Salmonella typhimurium also has a 
membrane bound lipid A modification system, which defends themselves against AMPs from the 
host [285]. In this system, PhoQ is a membrane bound sensor kinase and PhoP is intracellular 
response regulator. PhoQ is activated in the presence of high level positive charges outside the 
cells. It then phosphorylates the PhoP causing up-regulation of some genes including those 
related to AMP resistance. This system is not active when the extracellular level of Ca2+, Mg2+, 
or Mn2+ ions is low since divalent cations interact with PhoQ and change its conformation [110]. 
Although bacteria have diverse mechanisms for resistance to AMPs, it is encouraging to notice 
that the general lipid bilayer structure of bacterial membranes makes it hard to develop a 
complete resistance against AMPs. Also, the resistance against AMPs reported to date is not as 
strong as those against antibiotics and it only covers a limited number of AMPs. 
 
1.4 Outlook  
 
The urgent need to obtain new antimicrobials has been driving AMP research. With rapid growth 
in related knowledge and lead compounds, more AMPs may enter clinical tests and treatment in 
the near feature. However, infection control by AMP is still hindered by several challenges 
including low specificity, high manufacturer cost, potential toxicity to animal cells, and lack of a 
robust guideline for rational design. 
As we have seen from synthetic and modified AMP studies, it is easy to change characteristics of 
an AMP with even small modifications. However, predicting the results of these changes is still 
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challenging. Thus, there is a need to understand the effects of structural modifications on the 
physiochemical characteristics of AMPs as well as their target spectrum and activity. Recently, 
these types of studies have been increasing and computational approaches have been involved in 
AMP research. These efforts will help to better understand the mode of action of AMPs and 
predict their activities. 
Another understudied area is using AMPs to control antibiotic resistant bacteria, biofilms, and 
persister cells. These targets are highly resistant to traditional antibiotics and play important roles 
in infections. Since AMPs target cell membrane, they have good potential in such applications. 
On the other hand, because AMPs have not been well studied for biofilm and persister control, 
there might be some existing natural AMPs that are effective against these targets with potential 
synergy with antibiotics. Applying AMPs with biofilm matrix degrading enzymes might also be 
a good strategy to eliminate biofilms. Further development in this area and AMP research in 
general will benefit from close collaboration of different disciplines and new tools that can 
decipher the structure-function relationship and more efficiently synthesize and modify AMP 
molecules. 
To gain better fundamental understanding of the characteristics and antimicrobial activities of 
AMPs we have tailored different design approaches to develop better AMPs. Among these 
approaches, a dendrimeric peptide with repetitive functional groups on a branched core (2D-24, 
Chapter 2), a triazine derivative (TN-5, Chapter 3), which is a relatively new source for 
antimicrobial agent design, and a native human originated AMP with its neutral charged 
derivative (calcitermin, Chapter 5) were studied. The majority of AMPs targets cell membrane, 
disrupting its integrity and causing membrane depolarization. Having antimicrobial agents active 
on cell membrane holds a great potential with low risk for bacterial resistance since membrane 
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structure is present in all microorganisms and changing the content or structure of this lipid 
bilayer can be lethal to bacteria.  To better understand the membrane function and antimicrobial 
susceptibility, a new strategy to target cell membrane of persister cells was also evaluated with 
the antibiotic erythromycin (Chapter 4), which is the substrate of efflux pump AcrAB. 
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CHAPTER 2 
 
SYNTHETIC DENDRIMERIC PEPTIDE ACTIVE AGAINST BIOFILM AND 
PERSISTER CELLS OF PSEUDOMONAS AERUGINOSA 
 
 
 
 
 
 
 
 
This chapter has been published as below with minor modifications. Ali Adem Bahar, Zhigang 
Liu, Filbert Totsingan, Carlos Buitrago, Neville Kallenbach, Dacheng Ren. Synthetic 
dendrimeric peptide active against biofilm and persister cells of Pseudomonas aeruginosa. 
Applied Microbiology and Biotechnology 2015, 99, 8125-8135. 
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2.1 Abstract 
Antimicrobial dendrimeric peptides (AMDP) are a relatively new class of agents displaying 
repetitive functional groups on a branched core. Previous work done by Liu et al. in 2007 has 
investigated the length requirement for antimicrobial activity of peptides consisting of repeated 
arginine (R) and tryptophan (W) side chains and found that even short linear RW repeats are 
active, providing a starting point for a de novo design of multivalent structures. In this study, we 
tested a new synthetic dendrimer, 2D-24, for its antimicrobial activity against Pseudomonas 
aeruginosa, including the wild-type PAO1 and its mucoid mutant PDO300. This synthetic 
AMDP was found to kill planktonic cells of both PAO1 and PDO300 in a dose-dependent 
manner, with nearly complete killing of both strains observed when treated with 50 μM of this 
agent. In addition to planktonic cells, 2D-24 was also found to kill biofilm cells of both strains in 
a dose-dependent manner. For example, treatment with 30 μM 2D-24 led to 94.4 ± 1.4 and 
93.9 ± 4.2 % killing of PAO1 and PDO300 biofilm cells, respectively. Furthermore, 2D-24 was 
effective in killing multidrug-tolerant persister cells of PAO1 and PDO300. While higher 
concentrations of 2D-24 were required to kill persister cells, combinations of 2D-24 with 
ciprofloxacin, tobramycin, or carbenicillin showed synergistic effects on killing persister cells of 
both strains. Based on hemolysis assays using a co-culture model of PAO1 and human epithelial 
cells, 2D-24 was found to kill P. aeruginosa cells at concentrations that are not toxic to 
mammalian cells. 
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2.2 Introduction 
Bacteria have evolved diverse mechanisms to survive from the attack of antibiotics. One such 
mechanism involves persister cell formation, by which a small population in a bacterial culture 
enters an inactive stage and exhibits high tolerance to antibiotics and other forms of stress [1]. 
Consistently, persister cell formation has been implicated in chronic infections by 
Mycobacterium tuberculosis and Pseudomonas aeruginosa [2,3]. 
In addition to persister formation, bacteria can also evade antibiotics by forming multicellular 
structures, known as biofilms, in which bacterial cells adhere to a surface and secrete an 
extracellular matrix that protects them from environmental stresses [4]. Due to limited mass 
transfer [5], biofilm cells grow slowly with reduced metabolism and exhibit high tolerance to 
antimicrobial agents [6,7]. It is estimated that 80 % of bacterial infections in humans involve 
biofilms [8]. Thus, biofilms present a serious complication associated with chronic infections 
especially in patients with compromised immune systems [9-12]. 
To address the challenge of drug-resistant infections, it is important to develop new 
antimicrobials that are effective against biofilms and persister cells. Antimicrobial peptides 
(AMP) are promising alternative antibiotics due to their rapid killing effects, low frequency of 
resistance development, and broad spectrum of target microbes [13]. Thousands of AMPs have 
been identified to date [14], and many synthetic analogs have been developed and tested against 
infectious microorganisms including protozoa, fungi, bacteria, and viruses [15-19]. However, 
most AMPs are not appropriate for therapeutic use due to cytotoxicity, high MIC (minimum 
inhibitory concentration) values, in vivo inactivation by proteases, and/or high production cost 
[20]. Therefore, it is important to develop new AMPs to overcome these challenges. One such 
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strategy is to modify the AMP molecules by amidation of carboxyl ends [21], cyclization, 
covalent modification with disulfide bonds [22], and/or alteration of amino acid content such as 
adding prolines [23]. Modifications of this kind can affect critical physiochemical properties of 
natural AMPs and thus the target spectrum, cytotoxicity to eukaryotic cells, antimicrobial 
activity, and stability against proteases [13]. 
Antimicrobial dendrimeric peptides (AMDP) are a relatively new class of AMPs with repeating 
functional groups linked to a multivalent scaffold. The Kallenbach group has investigated the 
length requirement for antimicrobial activity of peptides only consisting of amino acid arginine 
(R) and tryptophan (W) repeats. Even short repeats of RW (trimers, for example) are active, 
providing a starting point for a de novo design of minimal structures [24]. Further studies found 
that dendrimeric displays of di- or tripeptides of arginine and tryptophan can render the AMPs 
more potent and less cytotoxic than natural AMPs [25]. Recently, the Ren lab showed that some 
synthetic AMPs with RW repeats are effective against planktonic and biofilm cells of 
Escherichia coli [26,27] including persister cells [28]. To further evaluate the potential of 
AMDPs as more effective antibacterial agents, the agent 2D-24, containing RWR and RTtbR(2) 
tripeptide branches (Fig. 2-1), was tested in this study for its antimicrobial activities against 
planktonic, biofilm, and persister cells of the wild-type P. aeruginosa PAO1 and its mucoid 
mutant PDO300. 
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Figure 2-1. Structure of 2D-24 
 
P. aeruginosa is a Gram-negative bacterium with exceptional capabilities to adapt to different 
living environments [29]. It is a well-known opportunistic human pathogen [30], causing serious 
infections in patients with comprised immunity or with cystic fibrosis [31,32]. P. aeruginosa can 
acquire antibiotic tolerance through biofilm and persister formation [33,34]. In addition, during 
chronic colonization in the lungs of cystic fibrosis patients, P. aeruginosa commonly acquires 
mutations that lead to a mucoid phenotype overproducing the polysaccharide alginate and 
therefore acquires a higher-level antibiotic tolerance [35-37]. With its strong clinical relevance, 
P. aeruginosa is a good model bacterium for studying antibiotic resistance and for testing new 
antimicrobials. 
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2.3 Materials and methods 
 
2.3.1 2D-24 Synthesis 
 
The synthesis of 2D-24 (50-μmol scale) was performed in the lab of Kallenbach at New York 
University.  
 
2.3.2 Bacterial strain and growth media.  
 
P. aeruginosa PAO1 (ATCC BAA-47, henceforth PAO1) and P. aeruginosa PDO300 (mucA22 
mutant of P. aeruginosa PAO1, constructed based on a clinical isolate of P. aeruginosa FRD1 
from cystic fibrosis patient [38]; henceforth, PDO300 [39]) were routinely cultured in Lysogeny 
broth (LB) medium [40] containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at 
37°C with shaking at 200 rpm. To minimize the difference in persistence between overnight 
cultures by freeze and thaw, all overnight cultures were inoculated with single-use glycerol 
stocks prepared from the same overnight culture of desired bacteria.  
 
2.3.3 Effects of 2D-24 on planktonic cells  
 
Exponential cultures were prepared by inoculating 3 mL LB medium with an overnight culture to 
an optical density at 600 nm (OD600) of 0.01 and incubated at 37°C with 200 rpm shaking until 
OD600 reached 0.5. Then, different concentrations of 2D-24 were added. The control and treated 
samples were incubated for 3 h at 37°C with 200 rpm shaking. Then, the cells were washed three 
times with phosphate buffered saline (PBS, pH 7.4). The viability of each sample was 
determined by counting colony-forming units (CFUs) using a drop-plate method as described 
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previously [28]. Briefly, each sample was diluted in a 10× series with 0.85 % NaCl solution. The 
CFU was determined by loading 10 μL of each diluted sample on a LB agar plate and counting 
the CFUs after incubation at 37°C overnight. 
 
2.3.4 Effect of 2D-24 on biofilms  
For each treatment, three separate polished (using 1000 grit sand paper, 3 M, St. Paul, MN, 
USA) sterile 2 cm × 1 cm 316-L stainless steel coupons were placed in a petri dish containing 
20 mL LB medium. To initiate biofilm formation, the medium was inoculated with an overnight 
culture to OD600 of 0.01. These coupons were incubated for 24 h at 37°C without shaking. The 
coupons were then washed gently with PBS three times and placed in a 12-well plate (one 
coupon in each well) with 2 mL PBS in each well and 2D-24 supplemented at concentrations of 
0.1 to 30 μM. After incubation for 3.5 h, biofilm coupons were washed with PBS and transferred 
to 15-mL sterile conical tubes with 3 mL PBS buffer in each. The samples were gently sonicated 
for 4 min in a sonication bath (Branson B200 Ultrasonic, Danbury, CT, USA) and vortexed for 
15 s (this condition was confirmed not to kill the cells; data not shown). The cells, thus detached 
from coupons, were plated using the drop-plate method [28] to determine the CFUs. 
 
2.3.5 Persister isolation and killing by 2D-24 
Persister cells of PAO1 and PDO300 were isolated by killing normal cells in overnight cultures 
with 200 μg/mL ciprofloxacin (Cip) for 3.5 h at 37°C, as described previously [41,42]. Longer 
treatment, 6.5 h, was also tested to confirm the treatment time was sufficient (no additional 
killing with extended time) as described in (Pan et al. 2012). After antibiotic treatment, surviving 
persister cells were washed twice with PBS buffer to remove any remaining antibiotic. The 
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collected cells were resuspended in 3 mL PBS supplemented with 2D-24 at different 
concentrations and incubated for 3.5 h at 37°C with 200 rpm shaking. After treatment, the cells 
were washed with PBS and plated to determine the viability by counting CFU as described 
above. 
 
2.3.6 Fluorescence microscopy  
To corroborate the CFU results, the LIVE/DEAD BacLight™ bacterial viability kit (Life 
Technologies Inc., Carlsbad, CA, USA) was used to determine the viability of biofilm cells of 
PAO1 and PDO300 on 316-L stainless steel coupons. The 24-h P. aeruginosa biofilms grown on 
these surfaces were washed gently with 0.85 % NaCl (w/v) solution three times to remove 
planktonic cells. Then, 1 μL of 20 mM propidium iodide and 1 μL of 3.34 mM SYTO 9 stains 
were added in 1 mL PBS to stain each biofilm sample for 10 min in the dark. The stained biofilm 
samples were examined with an Axio Imager M1 fluorescence microscope (Carl Zeiss Inc., 
Berlin, Germany). At least five randomly selected spots were examined for each sample. 
 
2.3.7 Synergistic effects between 2D-24 and antibiotics  
Three different antibiotics were tested including Cip (a fluoroquinolone targeting DNA gyrase) 
[43], tobramycin (Tob, an aminoglycoside targeting translation by binding to ribosome subunits) 
[44], and carbenicillin (Car, a carboxypenicillin targeting bacterial cell wall synthesis) [45]. 
Normal and persister cells of PAO1 and PDO300 were treated with antibiotic alone, 2D-24 
alone, or a combination of an antibiotic and 2D-24 to assess any synergistic effects in bacterial 
killing. The viability of bacterial cells was determined using the drop-plate method as described 
above. 
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2.3.8 Cytotoxicity and antimicrobial effects in co-cultures  
 
The cytotoxicity of 2D-24 on eukaryotic cells was evaluated using IB3-1 cells and 
LIVE/DEAD® viability/cytotoxicity kit (Invitrogen, NY, USA). IB3-1 cells were grown in 
LHC-8 basal medium (Invitrogen, NY, USA) supplemented with 10 % (v/v) fetal bovine serum 
(FBS) in flasks pre-coated with 100 μg/mL bovine serum albumin (BSA) and 30 μg/mL collagen 
at 37°C with 5 % CO2. All treatments were performed in antibiotic-free medium. To test the 
cytotoxicity, IB3-1 [46] (a compound heterozygote bronchial epithelial cell line from a CF 
patient) cells were seeded into black-sided clear-bottom 96-well plates (5 × 104 cells per well) 
and incubated until the cell density reached 1 × 106 cells per well. Then, 2D-24 was added at 
concentrations of 1 to 32 μM. After treatment for 24 h, EthD-1 and calcein AM were used to 
assess the viability of IB3-1 cells. The optimal concentrations of EthD-1 (1 μM) and calcein AM 
(2 μM) were determined prior to the treatments to label live and dead IB3-1 cells distinctively. 
After staining for 30 min at 37°C, samples were washed with PBS and analyzed using a 
fluorescence microplate reader (model FLx800, Bio-Tek Instruments, Winooski, VT, USA). To 
test the effects of 2D-24 on PAO1 in co-cultures, PAO1 cells (4 × 106 cells/mL) were added 
either with 2D-24 together or at 4 h prior to 2D-24 treatment (20 h after the inoculation of IB3-1 
cells). The viability of IB3-1 cells was determined as described above. To compare the effects on 
bacteria, PAO1 cells were treated in the same medium (LHC-8 basal medium) but in the absence 
of IB3-1 cells. The viability of PAO1 cells was determined by counting CFU using the drop-
plate method as described above. All treatments were tested in triplicate. 
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2.3.9 Statistical analysis  
The data from CFU experiments were analyzed with one-way ANOVA followed by Tukey test 
using SAS version 9.3 (SAS Institute, Cary, NC, USA). Differences with p < 0.05 were 
considered to be statistically significant. 
 
2.4 Results  
 
2.4.1 Antimicrobial effects of 2D-24 on planktonic cells  
 
First, the effects of 2D-24 on normal planktonic cells were evaluated by treating cells in 
exponential phase cultures with different concentrations of 2D-24. As shown in Fig. 2-2, 2D-24 
was effective in killing both PAO1 and PDO300 planktonic cells in a dose-dependent manner. 
For example, 5 μM 2D-24 was found to kill 53.3 ± 3.3 % PAO1 (p < 0.001) and 40.3 ± 6.2 % 
PDO300 (p < 0.005) cells, respectively. The killing efficiency increased with the concentration 
of 2D-24. At 20 μM, 79.9 ± 4.7 % (p < 0.001) and 84.6 ± 7.1 % (p  < 0.001) killing was obtained 
for PAO1 and PDO300, respectively. No viable cells of either strain were found after treatment 
with 50 μM 2D-24, suggesting that complete killing is possible. Interestingly, while the mucoid 
strain PDO300 is more tolerant to antibiotics than the wild-type PAO1 [37], 2D-24 exhibited 
similar activities in killing PAO1 and PDO300. 
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Figure 2-2. Effects of 2D-24 on planktonic cells of PAO1 (A) and PDO300 (B). The dendrimer 
2D-24 was added at different concentrations to exponential cultures, and the viability was 
determined by counting CFUs 
 
2.4.2 Antimicrobial effects of 2D-24 on biofilm cells  
In addition to planktonic cells, 2D-24 was also found to kill PAO1 and PDO300 biofilm cells 
effectively (Fig. 2-3). At 5 μM, 2D-24 is slightly more effective against PAO1 than PDO300. 
For example, 2D-24 exhibited 55.8 ± 6.5 % killing (p < 0.001) of PAO1 biofilm cells, while the 
killing of PDO300 biofilm cells with the same concentration of 2D-24 was 31.6 ± 8.8 % 
(p < 0.05). The activity increased with 2D-24 concentration for both strains, e.g., 2D-24 killed 
87.8 ± 3.1 % (p < 0.001) and 94.4 ± 1.4 % (p < 0.001) of PAO1 biofilm cells when treated at 20 
and 30 μM, respectively. Similar activities against PDO300 biofilms were observed, e.g., 2D-24 
exhibited 81.7 ± 3.5 and 93.9 ± 4.2 % killing of PDO300 biofilm cells when added at 20 and 
30 μM, respectively (p < 0.001 for both). Since the mucoid strain PDO300 is tolerant to multiple 
antibiotics [47,48], the finding that 2D-24 is equally effective in killing PAO1 and PDO300 
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biofilms is encouraging. The effective killing of biofilm cells, especially those of PDO300, 
suggests that 2D-24 is able to penetrate the biofilm matrix and the alginate layer of the mucoid 
strain. 
 
        
Figure 2-3. Effects of 2D-24 on PAO1 (A) and PDO300 (B) biofilm cells. The biofilms were 
cultured for 24 h in LB medium before treatment with 2D-24 for 3.5 h in PBS 
 
2.4.3 LIVE/DEAD staining of biofilms  
To corroborate the CFU results of biofilm killing, the control and 2D-24-treated biofilm samples 
were analyzed using LIVE/DEAD staining. Consistent with CFU data, the LIVE/DEAD images 
also showed dose-dependent killing of biofilms cells by 2D-24. While the cells in untreated 
control were healthy (green), killing was observed (red) with addition of 2D-24 and the effects 
were dose dependent (Fig. 2-4).  
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Figure 2-4. LIVE/DEAD images of PAO1 and PDO300 biofilms. A, B, C: PAO1 biofilms 
treated with 0, 10, and 30 μM 2D-24, respectively. D, E, F: PDO300 biofilms treated with 0, 10, 
and 30 μM 2D-24, respectively. Bar = 10 μm 
A
B
C
D
E
F
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2.4.4. Antimicrobial effects of 2D-24 on persister cells 
Because persister cells are highly tolerant to antibiotics [49], we were motivated to also test 2D-
24 against persister cells of PAO1 and PDO300 (Fig. 2-5). It was found that 2D-24 is effective in 
killing persister cells of both strains, although higher concentrations of 2D-24 than those required 
to kill normal cells are needed. For example, 200 μM of 2D-24 killed 68.7 ± 6.7 % (p < 0.001) of 
PAO1 and 89.0 ± 3.2 % (p < 0.001) of PDO300 persister cells. At concentrations below 50 μM, 
2D-24 exhibited a stronger killing effect on PAO1 persister cells compared to PDO300. For 
example, at 30 μM, 2D-24 showed 30.3 ± 6.1 % (p < 0.05) killing of PAO1 persister cells, while 
the same condition did not show any significant killing (p  = 0.08) of PDO300 persister cells. 
Interestingly, there was a sharp increase in the susceptibility of PDO300 persister cells between 
30 and 50 μM of 2D-24; the killing increased from 10.71 ± 6.2 to 87.6 ± 3.3 % (p  < 0.05) when 
2D-24 was added at 30 and 50 μM, respectively. These results suggest that a threshold may exist 
for the activity of 2D-24 to kill PDO300 persister cells effectively. 
 
         
Figure 2-5. Effects of 2D-24 on persister cells of PAO1 (A) and PDO300 (B). Persister cells 
were isolated by killing normal cells in overnight cultures with 200 μg/mL Cip for 3.5 h 
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2.4.5 Synergistic effects between 2D-24 and antibiotics 
Since some membrane-active AMPs can synergize with traditional antibiotics in bacterial killing 
[50], we also tested if the activity of 2D-24 can be enhanced through synergy with antibiotics. To 
achieve this, 1 μg/mL Cip, 1.5 μg/mL Tob, and 0.75 μg/mL Car (which can kill ~0.5 log of 
normal planktonic cells) were tested in the presence and absence of 2D-24. As shown in 
Figure 2-6, treatment with 1.5 μg/mL Tob or 5 μM 2D-24 alone killed 0.4 log (59.2 ± 0.7 %) and 
0.3 log (54.1 ± 1.7 %) of normal planktonic PAO1 cells, respectively. In comparison, co-
treatment with both agents caused 2.3 logs of killing (99.6 ± 0.6 %). Similar results were 
obtained for Cip and Car. Thus, there is indeed a synergy between 2D-24 and these three 
antibiotics. Co-treatments of normal planktonic cells of PDO300 with antibiotics and 2D-24 gave 
similar results. Thus, 2D-24 and the tested antibiotics show synergy in killing both strains. 
   
Figure 2-6. Co-treatment of planktonic PAO1 (A) and PDO300 (B) cells with 2D-24 and 
antibiotics. Cip, Tob, and Car antibiotics were tested on exponential cultures (OD600 = 0.5). 
Antibiotics or 2D-24 alone were used as controls 
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Previously, we reported that some membrane-active AMPs, containing tryptophan and arginine 
repeats, synergize with ampicillin in killing E. coli persister cells [28]. Thus, we tested if there is 
also a synergy in killing persister cells with 2D-24 and antibiotics. The results showed that there 
are synergies in killing persister cells, especially the co-treatment with 2D-24 and Tob (Fig. 2-7). 
For example, Tob (100 μg/mL) or 2D-24 (30 μM) alone killed <1.5 %  and 0.1 log (20.7 ± 1.4 %) 
of PAO1 persister cells, respectively. In comparison, co-treatment with these two agents led to 
0.58 log (73.8 ± 3.8 %) killing of persister cells. Similar results were obtained for PDO300 
persister cells. 
  
Figure 2-7. Co-treatment of PAO1(A) and PDO300 (B) persister cells with 2D-24 and 
antibiotics. Cip, Tob, and Car antibiotics were tested in the presence and absence of 30 μM 2D-
24. The persister cells were isolated from overnight cultures by killing normal cells with 
200 μg/mL Cip for 3.5 h. Antibiotics were tested at different concentrations (1–1000 μg/mL 
tested), but only the results of 100 μg/mL are shown. The CFU data of untreated controls in each 
run were normalized as 100 % for the convenience of data comparison across the samples 
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2.4.6 Cytotoxicity of 2D-24 on IB3-1 lung epithelial cell line in a co-culture with PAO1 
It is encouraging to find that 2D-24 is effective against the biofilm and persister cells of P. 
aeruginosa. To determine if 2D-24 is safe to mammalian cells at the effective concentrations, we 
further tested the cytotoxicity of 2D-24 on the IB3-1 lung epithelial cell line. The results showed 
that 2D-24 is not toxic to IB3-1 cells at concentrations up to 32 μM after treatment for 24 h 
(Fig. 2-8), e.g., no significant change in viability was found compared to the 2D-24-free control 
(p  = 0.28). In comparison, when PAO1 cells were treated by 2D-24 at the same concentration in 
the same medium, significant killing was observed. For example, 84.9 ± 9.5 % of PAO1 cells 
were killed by 16 μM 2D-24. Consistently, 2D-24 was found to protect IB3-1 epithelial cells 
from the infection of PAO1 in a co-culture model. In the absence of 2D-24, only 45.7 ± 2.6 % of 
IB3-1 cells remained viable after 24 h incubation with PAO1. In comparison, the presence of 
2D-24 increased the viability of IB3-1 cells in a concentration-dependent manner. For example, 
94.7 ± 2.7 and 82.6 ± 5.2 % of IB3-1 cells remained viable when 16 μM 2D-24 was added along 
with the inoculation of PAO1 and at 4 h after inoculation, respectively. 
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Figure 2-8. Cytotoxicity of 2D-24 on IB3-1 cells and the effects in a co-culture model. Different 
2D-24 concentrations, from 1 to 32 μM, were tested on IB3-1 cells alone (circles), added 
together with PAO1 inoculation (squares), or 4 h after PAO1 inoculation (triangles). Besides, 
PAO1 cells alone in LHC-8 medium with no IB3-1 cells (crossings) were treated with the same 
concentrations of 2D-24 to evaluate bacterial killing. The viability of IB3-1 cells was determined 
using the LIVE/DEAD staining kit by following the manufacturer’s protocol. The viability of 
PAO1 was determined by counting CFUs 
 
2.5 Discussion 
Although more than 5000 AMPs have been identified to date [51], most previous studies of their 
activities have focused on activities against normal planktonic bacterial cells [13]. In 
comparison, the effects of AMPs on biofilm cells have been less studied, and few reports exist 
regarding their effects on persister cells. In this study, a new synthetic AMDP, 2D-24, was tested 
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against planktonic and biofilm cells, including persister cells of P. aeruginosa PAO1 and 
PDO300. Significant killing effects were observed for all the cell types tested. 
Most synthetic AMPs are designed based on the characteristics of natural AMPs. In general, they 
are positively charged, amphiphilic molecules [52,53] and act on negatively charged cell walls 
and membranes, impairing the membrane potential and leading to cell death [13]. AMPs have a 
wide spectrum of target microbes. It has been postulated that the effectiveness of AMPs on 
bacteria depends on the peptide/lipid ratio during treatment [54]. In this study, the killing of 
PDO300 persister cells increased drastically when the concentration of 2D-24 reached 30 μM, 
which indicates that the killing may be dependent on peptide/lipid ratio as well. However, the 
biofilm and normal planktonic cells of PDO300 and all types of PAO1 cells tested here did not 
show a threshold concentration of 2D-24 for killing. It will be helpful to further investigate if 
persister formation affects the interaction between 2D-24 and the cell membrane of this mucoid 
strain. 
Biofilms are composed of bacterial populations that include cells at different stages embedded in 
a complex extracellular matrix [55]; cells in biofilms can be up to 1000 times more tolerant to 
antibiotics than their planktonic counterparts [56]. Intriguingly, 2D-24 appeared to be equally 
effective against normal planktonic cells and biofilm cells of PAO1 and PDO300. This finding 
suggests that 2D-24 can penetrate biofilm matrix and is effective in killing biofilm cells. In 
comparison, persister cells tolerated higher concentrations of 2D-24. Overall, concentrations 
higher than 20 μM of 2D-24 were found sufficient to kill more than 80 % of both planktonic and 
biofilm cells of PAO1 and PDO300, while concentrations higher than 50 μM are required to 
achieve a similar level of killing of persister cells of these strains. Interestingly, when treated 
with higher concentrations of 2D-24, persister cells of PDO300 were slightly more susceptible 
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than PAO1 persister cells. For example, 50 and 200 μM 2D-24 exhibited 19.8 and 57.3 % more 
killing of PDO300 persister cells compared to PAO1, respectively. 
Mucoid conversion with overproduction of alginate is thought to play an important role in 
chronic infections by P. aeruginosa [57] since mucoid strains are generally more tolerant to 
antibiotics than the wild-type strain [47,48]. It is interesting that the killing effects of 2D-24 on 
biofilm cells of PDO300 and PAO1 were similar. This suggests that 2D-24 is able to penetrate 
alginate and interact with PDO300 cellular targets. 
Besides the killing of P. aeruginosa cells by 2D-24 alone, intriguing synergistic effects were 
observed when the cells were treated with 2D-24 and Cip, Tob, or Car, which are antibiotics 
targeting DNA, protein, and cell wall synthesis, respectively. Similar synergistic effects were 
observed for killing both PAO1 and PDO300 normal planktonic and persister cells (Figs. 2-6 and 
2-7). Among these antibiotics, the strongest synergy was observed for Tob, while Cip exhibited 
lower synergy. This is probably because the persister cells had been exposed to Cip during 
persister isolation. The mechanism of synergistic killing of bacteria by 2D-24 and antibiotics is 
unknown. Most AMPs target cell membrane and thus alter the membrane potential [13]. We 
speculate that membrane disruption, depolarization, or permeabilization by 2D-24 can lead to 
reduced membrane potential along with lower energy production. This may favor the penetration 
of cell membrane by some antibiotics, which is consistent with a recent study by Schmidt et al. 
[58] showing a peptide-tobramycin conjugate -Pentobra- can effectively enter the cells of P. 
aeruginosa, E. coli, and Staphylococcus aureus. The peptide domain of this molecule is rich in 
arginine and tryptophan residues (RQIKIWFQNRRW), similar to the amino acid content of 2D-
24. 
 96 
 
We speculate that the increase in intracellular antibiotic concentration along with membrane 
damage by 2D-24 may render the persister cells unable to wake up, leading to cell death. 
Alternatively, it may also be possible that the stress response to 2D-24 treatment could activate 
certain cellular activities targeted by antibiotics and thus increase the antibiotic susceptibility of 
persister cells. It will be interesting to test the effects of 2D-24 on the integrity of treated cells 
and compare the penetration of antibiotics through cell membrane in the presence and absence of 
2D-24. 
It is generally appreciated that AMPs and analogs can have more than one inactivating target in 
bacteria. Even though persister cells are known to be latent and different from normal active 
cells, they still need to maintain intact cell membrane structures. While the cell surface and 
membrane are generally implicated in the antibacterial action by AMPs, we still lack a complete 
understanding of the detailed mechanism(s) involved. Similar to bactericidal antibiotics, we 
recently reported that a different AMDP analog, (RW)4D, generates hydroxide radicals in target 
bacterial cells via a Fenton reaction [59]. It will be interesting to study the interaction of 2D-24 
with cellular targets among regular planktonic, persister, and biofilm cells of P. aeruginosa. 
In addition, we obtained data showing that 2D-24 is effective in killing P. aeruginosa at 
concentrations not toxic to IB3-1 epithelial cells. Similar to the uninfected control, the viability 
of IB3-1 cells increased to near 90 % when 2D-24 is added into the culture medium together 
with PAO1 at inoculation. This finding is intriguing since cytotoxicity is a major challenge in 
bacterial control with AMPs. Further in vivo tests will help evaluate the clinical potential of this 
new dendrimer. 
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In summary, a new antimicrobial dendrimer 2D-24 was tested for its effects on the biofilm and 
planktonic cells (including persister cells) of PAO1 and its mucoid mutant PDO300. Similar 
killing activities were observed for regular planktonic and biofilm cells of both strains, and this 
agent was also found to kill persister cells of both strains. Synergy between 2D-24 and 
antibiotics in killing P. aeruginosa was also observed. Further testing using co-cultures of PAO1 
and human IB3-1 cells demonstrated that 2D-24 is effective against bacteria at concentrations 
nontoxic to mammalian cells. Thus, our in vitro data provide encouraging evidence for potential 
application of 2D-24 in treatment of chronic infections caused by P. aeruginosa. In addition to 
the investigation of mechanistic aspects of 2D-24 action, animal studies will be needed to 
demonstrate its efficacy in vivo. 
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CHAPTER 3 
 
CONTROLLING PERSISTER AND BIOFILM CELLS OF GRAM-NEGATIVE 
BACTERIA WITH A NEW 1,3,5-TRIAZINE DERIVATIVE 
 
 
 
 
 
 
 
 
This chapter has been published as below with minor modifications. Ali Adem Bahar, Zhigang 
Liu, Meagan Garafalo, Neville Kallenbach and Dacheng Ren. Controlling Persister and Biofilm 
Cells of Gram-Negative Bacteria with a New 1,3,5-Triazine Derivative. Pharmaceuticals 2015, 
8(4), 696-710. 
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3.1 Abstract 
 
Infections caused by multidrug-resistant bacteria have been on the rise. This important issue 
presents a great challenge to the healthcare system and creates an urgent need for alternative 
therapeutic agents. As a potential solution to this problem, antimicrobial peptides (AMPs) have 
attracted increasing attention due to their broad spectrum of targeted microbes. However, most 
AMPs are expensive to synthesize, have relatively high cytotoxicity to mammalian cells, and are 
susceptible to proteolytic degradation. In order to overcome these limitations, novel synthetic 
AMPs are desired. Using 1,3,5-triazine (TN) as a template, several combinatorial libraries with 
varying cationic charge and lipophilicity were designed and screened by the Kallenbach lab. 
From this screening, TN-5 was identified as a potent lead. In the present study, this compound 
was tested for its antimicrobial activities on Escherichia coli and Pseudomonas aeruginosa. In 
addition to regular planktonic cells, the effects on biofilms and persister cells (metabolically 
inactive and antibiotic tolerant subpopulation) were also investigated. TN-5 was found to have a 
minimum inhibitory concentration (MIC) of 12.8 µM for both species and kill regular planktonic 
cells of both species dose dependently. TN-5 is also effective against persister cells of both E. 
coli and P. aeruginosa. The killing of biofilm cells of the mucoid P. aeruginosa PDO300 was 
enhanced by alginate lyase. 
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3.2 Introduction 
Since the discovery of penicillin in 1928 [1] and the achievement of economical production of 
this antibiotic in the 1940s [2], the use of antibiotics has been a crucial step in controlling 
infectious diseases with numerous lives saved [3]. However, the emergence and spread of 
antibiotic resistant microorganisms have rendered many antibiotics ineffective [4]. Such rapid 
development of multidrug resistant bacteria coupled with the insufficient investment in 
antimicrobial research has led to a concerning decline in effective therapies against bacterial 
infections, which presents a serious public health problem [5]. 
In addition to antibiotic resistance based on drug resistance genes [6], bacteria also exhibit high 
level antibiotic tolerance by forming persister cells (dormant subpopulation of phenotypic 
variants [7] and biofilms (surface attached structures with bacterial cells embedded in an 
extracellular matrix secreted by attached cells [8]). Persister cells and biofilms are not based on 
drug resistance genes; however, they allow bacteria to survive the treatment with potent 
antibiotics and facilitate the development of drug resistant strains through mutation and 
horizontal gene transfer [9]. 
According to the U.S. Centers for Diseases Control and Prevention, 80% of all infections in 
developed countries are associated by biofilms [10]. The biofilm matrix serves as a protective 
barrier, making bacterial cells more tolerant to antibiotics as well as host defense [11]. Biofilms 
are also enriched in persister cells. Thus, even if an antibiotic can penetrate the biofilm matrix, it 
might only kill normal cells within a biofilm population. After the course of antibiotic treatment, 
persister cells revive and repopulate the biofilm, which in turn causes an infection to relapse 
[10]. 
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An additional concern with biofilms of Pseudomonas aeruginosa is their ability to convert to 
mucoid variants [12]. A mucoid strain is characterized by overproduction of the 
exopolysaccharide alginate, with increased tolerance to some antibiotics [13] and phagocytosis 
by human macrophages [14], as well as enhanced protection from dehydration [15]. In cystic 
fibrosis patients, the leading cause of mortality is a respiratory failure due to chronic lung 
infection with P. aeruginosa strains that undergo mucoid conversion [12]. Mucoid isolates 
typically coincide with persistent chronic infection in cystic fibrosis patients. 
The challenges of drug tolerant infections have created an urgent need for new antimicrobials 
and treatment strategies. Recent research has shown the great potential of antimicrobial peptides 
(AMPs) as a class of powerful agents against both Gram-positive and Gram-negative bacteria 
[16,17]. A wide range of AMPs are naturally produced by the innate immune system of 
multicellular organisms in response to infections [18]. These AMPs are a unique group of 
molecules with a varying number of amino acids (generally from 12 to 50), including positively 
charged residues (such as arginine, lysine, or histidine) and a large proportion of hydrophobic 
residues. In humans, AMPs are found mainly in the tissues and organs that are exposed to 
airborne pathogens [19]. 
The structure and charge of an AMP play a major role in the mechanism of its actions. AMPs are 
generally cationic molecules with both hydrophobic and hydrophilic faces [20]. This 
amphipathic characteristic helps these molecules to integrate into the lipid bilayer membranes 
[21]. Membrane integrity disruption (via interaction with negatively charged cell membrane), 
inhibition of macromolecule (protein, DNA and RNA) synthesis, or interaction with certain 
intracellular targets are thought to be the primary mechanisms in AMP lethality [22]. Positively 
charged side chains in AMPs enable an initial nonspecific electrostatic interaction with the 
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negatively charged cell membrane. This process is followed by the insertion of AMP molecule 
into cell membrane with the help of hydrophobic residues [23]. For example, in the AMPs LL-37 
and β-defensin, the cationic face is positioned on the opposite side of the hydrophobic face, 
which helps the penetration into the membrane [20]. 
AMPs afford promising candidates for novel therapeutic agents and complement traditional 
antibiotic therapies because of some unique advantages, including broad-spectrum activity 
(antibacterial, antiviral, and antifungal), less resistance by microbes, and related broad anti-
inflammatory activities [24]. A number of AMPs and derivatives have been developed as 
therapies for infectious diseases such as oral mucositis [25], pulmonary infections associated 
with cystic fibrosis [26], and some sexually transmitted diseases [27]. AMPs can be used alone, 
in co-treatment with antibiotics, or as stimulators for immune system and toxin inhibiting agents 
in septic shocks [24]. 
Despite the aforementioned advantages, wide applications of AMPs are still limited by several 
factors. They are generally expensive to synthesize [28], vulnerable to proteolytic degradation 
upon intravenous administration [29] and sensitive to environmental factors such as salt 
concentration, pH, and the presence of plasma and serum proteins [30]. Another challenge is that 
some AMPs are cytotoxic to host cells [31]. 
In order to overcome these challenges, a number of synthetic AMPs and AMP-mimetics have 
been developed. Based on the concept that cationic charge, size, and lipophilicity are recognized 
major factors determining the antibacterial activity of AMPs, recently, the Kallenbach lab 
designed and screened several combinatorial libraries based on 1,3,5-triazine as a scaffold. 
Several lead compounds with good antimicrobial activity and low hemolytic activity were 
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identified from the screening of hundreds of triazine compounds [32]. With further structure 
activity relationship analysis, the compound TN-5 was identified as a potent antimicrobial 
compound (the screening results will be published elsewhere). In this study, TN-5 (Fig. 3-1) was 
tested for its antimicrobial activity on E. coli and P. aeruginosa, including regular planktonic 
cells, persister cells, and biofilms. 
 
Figure 3-1. Chemical structure of TN-5.  
 
3.3 Material and methods 
3.3.1 Chemical synthesis of TN-5 
 
TN-5, N2 - (4-Aminobutyl) - N4 - benzyl - N6 – naphthalenemethyl - 2,4,6 – triamino - 1,3,5-
triazine, white solid, was synthesized by our collaborator in Kallenbach lab at New York 
University, using an orthogonal synthetic approach based on cyanuric chloride stepwise reaction 
with naphthalenemethylamine, benzylamine and Boc-1,4-diaminobutane  as documented 
previously [32].  
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3.3.2 Bacterial strains and growth media  
 
E. coli RP437 [33] was provided by Dr. John S. Parkinson at the University of Utah. P. 
aeruginosa PAO1 [34] and P. aeruginosa PDO300 [12] were obtained from Dr. Matthew Parsek 
at the University of Washington. All strains were routinely grown in Lysogeny broth (LB) 
containing 10 g/L NaCl, 5 g/L yeast extract, and 10 g/L tryptone with pH 7.0. To ensure 
consistent experimental conditions throughout this study, all overnight cultures of a particular 
strain were started with single-use glycerol stocks originating from the same culture. Each 
experimental condition was tested with three independent cultures (three biological replicates). 
 
3.3.3 Determining Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal 
Concentration (MBC) of TN-5 
TN-5 was tested at different concentrations against E. coli and P. aeruginosa strains to determine 
MIC and MBC values following a previously described protocol [35] with slight modifications. 
MIC is referred to the concentration of an antimicrobial agent, which inhibits the visible growth 
of a given bacterium completely by checking with unaided eye. MBC is referred to the minimum 
concentration of an antimicrobial agent required to completely kill all the tested bacterial cells of 
a particular strain by checking colony formation on the plates after treatment. Briefly, 
exponential cultures of bacterial samples were used to inoculate test samples with a cell density 
of 5x105 colony forming unit (CFU)/mL. TN-5 was tested at concentrations from 0.2 µM to 96 
µM, increasing logarithmically. Cultures grown without antimicrobial and sterile LB medium 
were used as positive and negative controls, respectively. All samples were adjusted to a final 
volume of 3 mL and incubated for 16-18 h at 37°C. After incubation, the concentrations with no 
visible growth were assigned by visual check to determine MIC. MBC value of TN-5 was 
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identified by spreading TN-5 (0.2 µM to 96 µM) treated cells (overnight in LB) on LB agar 
plates and checking for growth after 24 h. Three independent cultures for each concentration 
were tested for MIC and MBC tests. 
 
3.3.4 Effects on planktonic cells  
 
To examine the antimicrobial activity of TN-5, the planktonic growth of E. coli RP437, P. 
aeruginosa PAO1 and PDO300 with TN-5 added at different concentrations was examined. 
Overnight cultures of each strain were grown in 50 mL LB medium for 12-16 h at 37°C. 
Subcultures were then prepared by inoculating LB medium with overnight cultures to an optical 
density at 600 nm (OD600) of 0.01 and harvested when the OD600 reached 0.4-0.5. These 
exponential cultures were washed with phosphate buffered saline (PBS) three times. Cell pellets 
were washed with fresh PBS and resuspended in 20 mL PBS buffer. For the TN-5 treatment, 3 
mL of each sample was taken and mixed with TN-5 at different concentrations. The samples 
were incubated for 3, 6, 12 and 24 h at 37°C with shaking at 200 rpm, and washed three times 
with PBS. Then a serial dilution of each sample was performed and the cells were spread on LB 
agar plates for counting CFU. The amount of DMSO (solvent to dissolve TN-5 in stock 
solutions) was adjusted to be the same for all samples to eliminate any solvent effect. Each 
condition was tested with three independent cultures. 
 
3.3.5 Persister isolation and treatment  
To isolate persister cells, overnight cultures of P. aeruginosa PAO1 and P. aeruginosa PDO300 
strains were treated with 200 µg/mL ciprofloxacin (Cip) while exponential cultures of E. coli 
RP437 were treated with 100 µg/mL ampicillin (all for 3 h at 37˚C) to kill normal cells as 
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described previously [36-38]. Then the persister cells were harvested by centrifugation, washed 
with PBS three times to remove remaining antibiotic, and resuspended in 20 mL PBS. Aliquots 
(1 mL) of each sample were supplemented with TN-5 at different concentrations. Three 
replicates were tested for each condition and all samples were incubated for 3 h at 37°C with 
shaking at 200 rpm. No change in persister cell number was found before and after incubation 
for 3 and 6 h in PBS without TN-5 (regardless the presence of antibiotics; Fig. 3-2). After TN-5 
treatment, the samples were washed with PBS three times and plated to count CFU as described 
above. Each condition was tested with three independent cultures.  
   
 
Figure 3-2. The isolated persister cells remained persistence after incubation in PBS. After 
isolation, the persister cells were incubated with or without antibiotic for 3 and 6 h. The persister 
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cells of E. coli RP437 (A), P. aeruginosa PAO1 (B), and P. aeruginosa PDO300 (C) were 
studied. Ampicillin at 100 µg/mL and ciprofloxacin at 200µg/ml were used to treat E. coli and P. 
aeruginosa persister cells, respectively. 
 
3.3.6 Biofilm experiments  
 
To study the effects of TN-5 on biofilm cells of E. coli and P. aeruginosa, biofilms were grown 
on 2 cm x 1 cm 316L stainless steel coupons. Each coupon was polished with 220 Grit sandpaper 
(3M, Sandblaster, St. Paul, MN) on both sides and sterilized with 70% ethanol for at least 15 
min. The coupons were then dried in a 50°C oven for 15 min. Sterilization was confirmed by 
incubating three coupons in LB medium for 24 h at 37°C and checking the turbidity of the 
cultures. To culture biofilms, sterilized coupons were transferred into new sterile plates 
containing 20 mL LB medium. To initiate biofilm formation, each sample was inoculated to 
OD600 of 0.01 with an overnight culture. The coupons were incubated for 24 h at 37°C without 
shaking to grow biofilms. After 24 h incubation the coupons were washed gently with PBS three 
times to remove planktonic cells. Coupons were then placed in 12 well plates separately, each 
including a different concentration of TN-5 in 2 mL PBS buffer. The coupons were incubated for 
3 h at 37°C with no shaking followed by washing with PBS three times. Each coupon was then 
transferred into a 15 mL sterile conical test tube containing 3 mL PBS. Samples were gently 
sonicated for 4 min in a water sonication bath (Branson B200 Ultrasonic, Danbury, CT, USA) 
and then vortexed for 15 s. Three replicates were tested for each condition. The cells in the 
suspension were then spread on LB agar plates to count CFU as described above. Each condition 
was tested with three independent cultures. 
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Besides treating established biofilms, the capability of TN-5 to prevent biofilm formation was 
also evaluated by adding TN-5 prior to the inoculation of biofilm cultures. After incubation for 
24 h, the coupons were washed gently and the cells were removed from coupon surface by 
sonication and vortex for CFU count as described above.  
 
3.3.7 Co-treatment of alginate lyase and TN-5 on P. aeruginosa biofilm cells  
 
To determine the contribution of a biofilm degrading agent on killing by TN-5, we repeated 
biofilm killing experiments in the presence of 50 µg/mL alginate lyase during TN-5 treatments. 
The same protocols were used for P. aeruginosa PAO1 and PDO300 biofilms. Each condition 
was tested with three independent cultures. 
 
3.3.8 Statistical analysis 
 
The data from CFU experiments were analyzed with one-way ANOVA followed by Tukey test 
using SAS version 9.4 (SAS Institute, Cary, NC, USA). Differences with p<0.01 were 
considered as statistically significant. 
 
3.4 Results 
3.4.1 MIC and MBC values of TN-5 
 
TN-5 was found to completely inhibit the growth of E. coli RP437, P. aeruginosa PAO1, and P. 
aeruginosa PDO300 at the concentration of 12.8 µM (MIC, Table 1). The MBC value was found 
to be higher than 96 µM for all three strains.   
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Table 3-1. MIC and MBC values of TN-5 on bacterial strains used in this study (based on three 
biological replicates). 
 E. coli RP437 P. aeruginosa PAO1 P. aeruginosa PDO300 
MIC (µM) 12.8 12.8 12.8 
MBC (µM) > 96 > 96 > 96 
 
 
 
3.4.2 Antimicrobial effects of TN-5 on planktonic cells 
To further study the killing activity of TN-5, exponential cultures were used to test the effects of 
TN-5 on the viability of planktonic cells. TN-5 was found effective in killing all bacterial strains 
tested in this study (E. coli RP437, P. aeruginosa PAO1 and PDO300) dose dependently in 3 h 
(Fig. 3-3). Longer incubation times (up to 24 h) did not cause additional killing (Fig. 3-4). For E. 
coli RP437, TN-5 showed 20.3±2.5% (p=0.07), 55.6±8% (p<0.001), 84.6±8.5% (p<0.001), and 
99.9±0.1% (3.4 log; p<0.001) killing of the total population (>99% as normal cells) at 
concentrations of 5, 20, 50, and 100 µM, respectively (Fig. 3-3A). These results show that TN-5 
is highly effective against normal planktonic cells of E. coli RP437.  
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Figure 3-3. Effects of TN-5 on planktonic cells of E. coli RP437 (A), P. aeruginosa PAO1 (B), 
and P. aeruginosa PDO300 (C). TN-5 was added in exponential phase cultures at different 
concentrations and the viability after treatment was determined by counting CFU. All significant 
differences (compared to the TN-5 free control) with p<0.01 are marked with an asterisk 
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Figure 3-4. Extended treatment time did not increase the killing of planktonic cells of E. coli and 
P. aeruginosa by TN-5. Each sample was treated with 100 µM TN-5 for 3, 6, 12, or 24 h. Three 
independent replicates were tested for each condition. E. coli RP437 (A), P. aeruginosa PAO1 
(B), and P. aeruginosa PDO300 (C) were studied. 
Significant killing effects were also observed on planktonic cells of P. aeruginosa PAO1 and 
PDO300 strains. For example, killing of 22.7±6.7% (p<0.001), 61.8±4.5% (p<0.001), 
74.7±11.8% (p<0.001), and 97.8±10% (1.6 log; p<0.001) of P. aeruginosa PAO1 was observed 
when TN-5 was added at 5, 20, 50, and 100 µM respectively (Fig. 3-3B). For P. aeruginosa 
PDO300, significant killing was observed at 50 and 100 µM with 44.1±3.1% (p<0.001) and 
94.1±6.8% (1.23 log; p<0.001) of the total population (>99% as normal cells) killed, 
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respectively (Fig. 3-3C). These results show that TN-5 is also effective against normal 
planktonic cells of P. aeruginosa.  
 
3.4.3 Antimicrobial effects of TN-5 on persister cells 
 
TN-5 was found to kill persister cells of E. coli RP437, P. aeruginosa PAO1 and P. aeruginosa 
PDO300 (Fig. 3-5). The killing of E. coli RP437 persister cells was 33.8±0.8% (p<0.001), 
43.8±2.8% (p<0.001), and 96.3±3.0% (1.35 log; p<0.001) when TN-5 was added at 50, 100, and 
200 µM, respectively (Fig. 3-5A). 
Similarly, TN-5 was also able to reduce the viability of P. aeruginosa PAO1 persister cells 
where 79.6±2.9% (p<0.001) and 89.9±4.5% (p<0.001) of cells were killed by 100 μM and 200 
μM of TN-5, respectively (Fig. 3-5B). In comparison, TN-5 was less effective on persister cells 
of the mucoid strain P. aeruginosa PDO300, with only 33.2±5.6% (p<0.001) and 36.4±5.2% 
(p<0.001) killed by 100 μM and 200 μM of TN-5, respectively (Fig. 3-5C). This is likely due to 
the presence of alginate on the surface of the mucoid P. aeruginosa PDO300 cells [39], which 
may reduce the penetration by TN-5.  
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Figure 3-5. Effects of TN-5 on persister cells of E. coli RP437 (A), P. aeruginosa PAO1 (B), 
and PDO300 (C). The persister cells were isolated by treating exponential cultures of E. coli 
RP437 with 100 µg/mL ampicillin and overnight P. aeruginosa cultures with 200 µg/mL 
ciprofloxacin (both for 3 h). All significant differences (compared to the TN-5 free control) with 
p<0.01 are marked with an asterisk. 
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3.4.4 Antimicrobial effects of TN-5 on biofilm cells  
 
 
TN-5 exhibited effective and dose dependent killing of E. coli RP437 biofilms. Killing of 
78.5±30.2% (p<0.001) and 98.9±9.6% (1.24 log) (p<0.001) of E. coli RP437 biofilm cells was 
achieved when TN-5 was added at 100 and 200 µM, respectively (insignificant at 50 µM) (Fig. 
3-6). In addition to the effects on established biofilms of E. coli RP437, TN5 effectively 
prevented biofilm formation of all the strains used in this study. Complete biofilm inhibition of 
E. coli RP437 and P. aeruginosa (both PAO1 and PDO300) was achieved with 10 and 20 µM 
TN-5, respectively (Fig. 3-7). However, 100 µM TN-5 alone did not show significant killing of 
cells in established biofilms of P. aeruginosa PAO1 or PDO300 (p>0.1) (Fig. 3-8A and 3-8C).  
 
 
 
 
Figure 3-6. Effects of TN-5 on E. coli RP437 biofilms. The biofilms were cultured for 24 h in 
LB on stainless steel coupons prior to treatment with TN-5. All significant differences (compared 
to the TN-5 free control) with p<0.01 are marked with an asterisk. Note: Data are plotted in 
linear scale. 
Concentration of TN‐5 (µM) 
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Figure 3-7. Effects of TN-5 on biofilm formation of E. coli RP437 (A), P. aeruginosa PAO1 
(B), and P. aeruginosa PDO300 (C). Initial biofilm cultures were supplemented with TN-5 at 
different concentrations and incubated for 24 h at 37˚C.  Then coupons were sonicated and 
vortexed to count CFU in biofilms. Three independent replicates were tested for each condition. 
All significant differences (compared with the TN-5 free control) with p<0.01 are marked with 
an asterisk. 
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Figure 3-8. Effects of TN-5 alone and co-treatment with alginate lyase on P. aeruginosa 
PDO300 (A&B) and PAO1 (C&D) biofilms. The biofilms were grown for 24 h and treated with 
TN-5 alone or in combination with alginate lyase for 3.5 h. All significant differences (compared 
with the TN-5 free control) with p<0.01 are marked with an asterisk. The co-treatment with TN-
5 (at 50 or 100 µM) and 50 µg/mL alginate lyase caused significant killing than the control (with 
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no TN-5 and alginate lyase) for both P. aeruginosa PDO300 and PAO1, but only significantly 
increased the killing by TN-5 alone for P. aeruginosa PDO300. Note: Data are plotted in linear 
scale. 
We speculated that the lack of antimicrobial effects against P. aeruginosa biofilms is because of 
the presence of biofilm matrix. Alginate is a major component of biofilm matrix of the mucoid P. 
aeruginosa strains [13,39]. Thus we tested the concurrent treatment of P. aeruginosa biofilms 
with alginate lyase and TN-5. As shown in Fig. 3-8B and 3-8D, alginate lyase itself showed no 
effect on the viability of biofilm cells (p=1). However, the combination of TN-5 with alginate 
lyase increased the killing of PDO300 biofilms; e.g., addition of 50 µM alginate lyase increased 
the activity of 50 µM TN-5 on P. aeruginosa PDO300 biofilms from no significant killing 
(p=0.58) to 36.5±4.6% (p<0.005) and that of 100 µM TN-5 from insignificant killing (p=0.12) to 
57±9.6% (p<0.005), respectively (Fig. 3-8A vs. Fig. 3-8B). The addition of alginate lyase did 
not show the same effects on P. aeruginosa PAO1 biofilm cells; e.g., 50 µM alginate lyase did 
not increase the effects of 50 and 100 µM TN-5 (p>0.1) (by comparing the % of killing based on 
corresponding data between Fig. 3-8C & Fig. 3-8D). This is likely because alginate is not a 
major component of its biofilm matrix.  
 
3.5 Discussion 
 
AMPs have been proposed as a promising source of new antimicrobial agents [40-43]. Different 
strategies have been tested to achieve effective killing of microbes while maintaining low 
hemolytic activity. In some of these studies, Trp (W) and Arg (R) containing 1,3,5-triazine 
structures [32] and dendrimeric peptides [44] have been used as AMP templates and lead 
compounds with antimicrobial activities and low toxicity to red blood cells have been identified. 
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In this study, one of the triazine-1,3,5 derivatives, TN-5, was tested on Gram-negative bacteria E. 
coli and P. aeruginosa. TN-5 was found to be effective against both species. The killing of 
persister and biofilm cells is of particular interest because these cells are difficult to eliminate 
and conventional antibiotics are generally ineffective. Our results show that TN-5 alone is 
effective against persister and biofilms of E. coli RP437 with up to 2-log killing achieved at 200 
µM. It is also interesting that TN-5 caused more killing of biofilm cells than planktonic persister 
cells of E. coli. For example, 100 µM TN-5 killed 43.8±2.8% and 78.5±30.2% of persister and 
biofilm cells of E. coli RP437, respectively. This finding suggests that TN-5 can penetrate the 
biofilm matrix of E. coli. 
Comparable effects were not observed for P. aeruginosa biofilms, however, possibly due to the 
difference in biofilm matrices. With a thick layer of alginate, biofilms of mucoid bacteria have 
high-level tolerance to some antimicrobials [13]. Thus, breaking down alginate in the biofilm 
matrix could be essential for certain antimicrobials to kill biofilm cells, especially the agents that 
can be absorbed or neutralized by the matrix components. Consistently, we found that the killing 
of P. aeruginosa PDO300 biofilm cells was enhanced by alginate lyase. It is worth noting that 
TN-5 is effective against P. aeruginosa PDO300 persister cells, but not its biofilm cells. Thus, it 
will be interesting to study if and how TN5 interacts with alginate directly and if there is any 
difference in the amount and structure of alginate between biofilm matrix and the surface of 
mucoid cells. In comparison, the killing of P. aeruginosa PAO1 biofilms was not enhanced by 
alginate lyase. This is consistent with the report [45] that alginate is not the primary component 
of P. aeruginosa PAO1 biofilm matrix. It will be interesting to test other matrix degrading 
enzymes, such as DNase.  
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In a previous study performed in our lab, Trp- and Arg- containing synthetic antimicrobial 
peptides were shown to inhibit 95.0 ± 1.1% of biofilm formation at 200 µM [46]. Intriguingly, 
TN-5 inhibited biofilm formation of both E. coli and P. aeruginosa completely at 20 µM (Fig. 3-
7). Therefore, TN-5 may also be an important antimicrobial agent for biofilm control.  
The mechanism of bacterial killing by TN-5 or in fact any AMP deserves more study. The 
positive charge of the arginine (R) side chain can help an AMP to interact with negatively 
charged lipopolysaccharides in Gram-negative bacterial walls [47]. Tryptophan (W) residues 
favor location below the head groups of bilayers, and are assumed to provide lipophilic 
interaction sites which cause membrane disruption [48]. Thus, RW mimicking TN-5 might target 
the negatively charged bacterial cell membrane. Another observation is that TN-5 mode of action 
occurs within the first 3 h (Fig. 3-2). 
E. coli is generally more susceptible to antibiotics than P. aeruginosa. Among 47 antimicrobial 
agents tested in an early study [49], only tobramycin showed the same MIC value (0.5 µg/mL) 
for E. coli (NCTC 10418 and ATCC 25922) and P. aeruginosa (NCTC 10662 and ATCC 27853) 
reference strains. The other antimicrobial agents tested all showed higher (up to 500 fold) MIC 
values for P. aeruginosa compared to E. coli [49]. Interestingly, TN-5 showed the same MIC 
value (12.8 µM) for both species in our study, which also indicates possible membrane targeting 
activities.  
Overall, this study shows that the triazine derivative TN-5 is a promising lead compound for 
developing new synthetic AMPs. It is encouraging that TN-5 is effective against both E. coli and 
P. aeruginosa at different growth stages. Persister cells of Pseudomonas strains, especially those 
of the mucoid strains, are highly resistant to antibiotic treatments. Because most AMPs kill 
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microbes through mechanisms that differ from those of conventional antibiotics, e.g. by targeting 
cell membranes, the killing effect of TN-5 on persister cells might be increased by synergy with 
some antibiotics if TN-5 can be effectively delivered to target cells. We assume that triazines are 
not susceptible to proteolytic degradation since there is no specific motif to trigger cleavage. 
Future experiments with mammalian cells and animal models are needed to evaluate the 
potential to use TN-5 and antibiotics together as a novel therapy for chronic infections involving 
biofilms and persister cells. 
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CHAPTER 4 
 
CONTROLLING PERSISTER CELLS BY TARGETING MEMBRANE POTENTIAL 
DEPENDENT ANTIBIOTIC EFFLUX 
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4.1 Introduction 
Persister cells were first defined in 1944 when Bigger showed surviving Staphylococcus after 
penicillin treatment. Re-inoculation of surviving cells gave rise to colonies, the majority of 
which can again be lysed by penicillin [1]. Forming metabolically inactive cells is one of the 
major strategies of bacterial survival in harsh conditions such as antibiotic treatments and host’s 
immune reactions. These dormant persister cells are highly tolerant to antibiotics and thus serve 
as a reservoir for the population to reestablish after the treatment leading to recalcitrance of 
chronic infections [2].  
To date, the mechanism of persister formation and physiological characteristics of persister cells 
are still not fully understood. Shah et al. [3] labeled E. coli ASV cells with a unstable GFP to 
follow cell growth activities with fluorescence under the control of ribosomal rrnBP1 promoter. 
Fluorescence-activated cell sorting (FACS) based on GFP gave two distinct populations; the 
bright normal cells and dim persister cells. Visualization with microscopy and further antibiotic 
treatment of these two populations revealed that persister cells are shorter than normal cells. 
Persister also exhibits a gene expression profile with increased level of SOS stress response, 
phage-shock and heat and cold-shock genes [4].  
Previous efforts to determine the genes specifically responsible for persister formation by 
screening knock-out mutant libraries have been largely unsuccessful [5,6]. Increasing evidence 
indicated that there are redundant pathways leading this dormancy stage. Some best 
characterized systems associated with persistence include toxin/antitoxin (TA) modules and the 
SOS response system. For example, persister cells have increased level of TisB protein, which 
decreases proton motive force and the ATP level and thus causes the cells to enter dormancy [2].  
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Essentially all bacterial populations include a small portion of persister cells [7]. These cells 
have low cellular energy due to their dormancy. Normal bacterial cell membrane has relatively 
high transmembrane potential, between –120 to –200 mV, which is important to ATP production 
and provides energy for many cellular processes [8]. Thus we hypothesize that persister cells 
have lower membrane potentials than normal cells and this temporary metabolic downshift might 
inactivate efflux based antibiotic resistance mechanism leading to intracellular accumulation of 
antimicrobials and kill persister cells during wakeup.  
Bacterial cell membrane is a semipermeable phospholipid bilayer with embedded proteins. This 
membrane plays an important role in the growth and stress response of bacteria. It is also the part 
of cell that antibiotics must penetrate to take action. The membrane permeability is affected by 
its composition [9]. Transporters, ion channels, ATP synthases, receptors, antigens and some 
signaling proteins are found in the membrane and represent about one third of the total proteins 
in a cell. These proteins are responsible for many important biological functions such as cell–cell 
contact, surface recognition, signaling, enzymatic activities, and transporting substances across 
the membrane [10]. An important function of cell membrane is to generate proton motive force, 
which requires the activities of ATP synthases, motility, DNA repair, and synthesis of 
macromolecules such as polysaccharides, proteins, nucleic acids, and numerous other processes 
in all living cells. Therefore, disturbance of membrane potential may have profound effects on 
the physiology and viability of bacterial cells.  
Energy-dependent drug efflux systems embedded in cell membranes play an important role in 
bacterial drug resistance [11,12], which requires proton motive force generated with appropriate 
membrane potential [13]. Most efflux pumps are proton pumps with a broad spectrum of target 
substrates [14]. For example, E. coli cells are resistant to erythromycin molecules via such efflux 
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pumps [15] and this activity depends on the energy produced by ATP synthase [16]. Some efflux 
pumps and their substrate antibiotics are summarized in Table 4-1.  
 
Table 4-1. Bacterial efflux pumps and substrate antibiotics 
Efflux 
family 
Efflux 
pump Resistance against Ref 
RND AcrAB Eyrthromycin, tetracycline, chloramphenicol, 
clarithromycin, ampicillin, nalidixic acid, and 
rifampin 
[17, 18] 
ABC YbjYZ Clarithromycin, azithromycin, erythromycin [15, 19] 
MFS MdfA Rifampin, tetracycline, chloramphenicol [20] 
MATE NorM, 
YdhE 
Norflaxacin, fluoroquinolones, rhodamine 6G, 
acriflavine, berberine, novobiocin, enoxacin, and 
tetraphenylphosphonium chloride 
[21-23] 
SMR EmrE Tetracycline and tetraphenylphosphonium [24] 
 
It has been reported that efflux pump mutants of Mycobacterium accumulate more ethidium 
bromide (EtBr) inside the cells and consequently higher susceptibility to antimicrobials; such as 
rifampicin, ethambutol, ciprofloxacin, streptomycin, amikacin, clarithromycin and erythromycin 
[25]. All these antimicrobial agents act on energy-dependent metabolic pathways such as RNA 
synthesis (rifampicin), cell wall synthesis (ethambutol [26]), protein synthesis (streptomycin, 
amikacin, clarithromycin, and erythromycin [27-30]), and function of DNA gyrase [31].  
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Efflux pumps have a wide variety of substrate antibiotics. For example, erythromycin, 
tetracycline and chloramphenicol, which target protein synthesis by binding and inhibiting 
ribosome complex, are all substrates of RND efflux family. These pumps are widespread 
especially in Gram-negative bacteria and are active against many different antibiotics [32].  
To test if persister cells have lower membrane potentials than normal cells, we characterized the 
membrane potential and efflux activities of normal and persister cells of E. coli and compared 
the killing effects of erythromycin, chloramphenicol and tetracycline on normal and persister 
cells of E. coli. These antimicrobial agents were chosen among ribosome targeting antibiotics. 
Under normal conditions E. coli efflux pumps use these antibiotics as substrate [18, 33-36]. 
However this efflux pump activity requires membrane potential and proton motive force. 
Therefore lower membrane potential may result in accumulation of antibiotics in treated cells.  
Erythromycin, which is a macrolide antibiotic, generally shows bacteriostatic effect by inhibiting 
protein synthesis. Since it targets the ribosome complex, the production of all the peptides 
including the ones essential to bacteria survival is inhibited. Erythromycin is used to treat several 
serious bacterial infections, such as pneumonia, bronchitis, diphtheria, pertussis, rheumatic fever, 
and epithelial infections. In 1986 no clinical isolate was found resistant to erythromycin [37]; 
however, a study in 2009 [33] showed that the majority of bacterial strains among 190 isolates 
collected from 5 different countries have MIC values higher than 128 µg/mL, indicating a rapid 
development of resistance. Erythromycin susceptibility can be restored with an AcrAB-TolC 
efflux pump inhibitor in E. coli [18]. Therefore, we hypothesize that lower membrane potential is 
expected to inhibit the activity of efflux pumps and increase the susceptibility of E. coli cells to 
erythromycin.  
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4.2 Materials and Methods 
 
4.2.1 Efflux activity  
 
The activity of efflux pumps was monitored with EtBr, by measuring its accumulation inside the 
cells. EtBr gives strong fluorescence when interacting with nucleotides [38] and can be pumped 
out by efflux systems of E. coli in the presence of proton motive force across cell membrane. 
Thus, the accumulation of EtBr inside the cells is a cumulative result of membrane permeability 
and efflux activity [39].  
E. coli Top10 pBAD hipA, a strain with inducible persister formation (engineered by Jing Wang 
in Ren lab) was used to test efflux activities. This strain can form large number of persister cells 
upon induction of hipA gene expression by 0.2% arabinose. E. coli Top10 pBAD hipA culture 
was grown in Lysogeny broth (LB) containing 10 g/L NaCl, 5 g/L yeast extract, and 10 g/L 
tryptone with pH 7.0.  
To induce persister formation, O/N culture of E. coli Top10 pBAD hipA was sub-cultured with a 
starting cell density of 0.01 at OD600 and incubated till the OD600 reached 0.15-0.2. Then the 
culture was supplemented with 0.2% arabinose and incubated for another 3 h at 37˚C with 
shaking at 200rpm to induce the persister formation. Additionally, 50 µg/mL tetracycline was 
added and incubated for 0.5 h following arabinose induction for further persister formation. After 
induction with arabinose and tetracycline, the culture was harvested by centrifuging at 10,000g 
for 8 minutes and resuspended in PBS by gently vortexing for 15 seconds. These cells were 
washed again with PBS and used for EtBr staining and persister count.   
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A portion of each induced and uninduced sample was taken and used to determine the 
persistence level by treating with 100 µg/mL ampicillin and counting CFU. The rest of each 
sample was treated with 25µg/ml EtBr to evaluate membrane permeability by measuring 
fluorescent signal from EtBr-nucleic acid complex of the cells. Following EtBr treatment, the 
cells were washed with PBS to get rid of excess EtBr signal in extracellular media and 200 µL 
cell suspension from each treatment was plated in a clear bottomed black walled 96 well plate for 
measuring fluorescence using a microplate reader (model FLx800, Bio-Tek Instruments, 
Winooski, VT, USA) with excitation at 360 nm and emission at 590 nm in PBS. Each 
experimental condition was tested with three independent cultures (three biological replicates). 
 
4.2.2 Flow-cytometer compensation and analysis of EtBr treated samples 
 
Flow cytometry was used to corroborate the results following persister induction and EtBr 
staining. To compare with the results of the wild-type E. coli K12, we also tested a ΔacrB mutant 
strain obtained from the Keio collection [40]. This mutant lacks efflux pump activity regardless 
the membrane potential. The exponential cultures of E. coli ΔacrB were stained with 25µg/ml 
EtBr for 10 minutes. Then excess EtBr dye was washed away with PBS. The changes in 
fluorescence intensity were determined using flow cytometry (Fig. 4-1).  
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Figure 4-1. The principle of flow cytometry. The cells are dispersed in a stream of fluid so that 
they can individually travel through fine tubing and detected. The signal from each event is 
recorded by a computer and analyzed.  
 
To test EtBr staining of persister cells with flow cytometry, an exponential culture of E. coli 
Top10 pBAD hipA was induced with 0.2% arabinose as described previously and compared with 
an uninduced control by staining with EtBr and analyzing with flow cytometry. In addition to the 
efflux mutant and high persistence strain, exponential culture of E. coli ASV strain was also used 
with flow cytometry to test if there is a higher EtBr accumulation in persister cells (dim 
population).   
Laser 
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4.2.3  Comparing membrane potential of persister and normal cells with potentiometric 
dye and flow cytometry 
 
To corroborate the EtBr results and further understand if persister formation affects membrane 
potential, we used a potentiometric dye, JC-1, to compare the membrane potential of normal 
planktonic cells and persister cells. JC-1 stains mitochondria and bacterial cells based on 
membrane potential [41]. This dye can give two different colors; red fluorescence when the dye 
molecule aggregate and green fluorescence from free dye molecules. With a high membrane 
potential, more JC-1 molecules can aggregate on the membrane and emit red fluorescence. In 
comparison, when the membrane potential lowered; less JC-1 accumulates in the membrane. 
This leads fluorescence dye in cytoplasm to give a green color. Thus a shift in red/green 
fluorescence can indicate the change in membrane potential.  
To perform this experiment, a high persistence strain, E. coli Top10 pBAD hipA, was grown 
exponentially at 37°C by shaking with 200 rpm till OD600 reached 0.2-0.3. Then the cells were 
washed with centrifugation and resuspended in PBS. Ten µL JC-1 dye was added per 100 – 300 
µL cell sample. After gentle mix by slightly tapping the tubes, cell and potentiometric dye 
mixture was incubated at 37°C for 15 minutes in dark. After incubation, the cells were 
centrifuged and excess JC-1 dye was washed away. Immediately after washing, samples were 
analyzed with flow cytometry by monitoring green and red fluorescence.  
 
4.2.4 Activity of efflux substrate antibiotics on persister cells  
Persister cells of E. coli HM22 and Top10 pBAD hipA strains were isolated as described 
previously. Isolated persister cells were treated with erythromycin, tetracycline and 
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chloramphenicol for 3.5 h at 37°C with 200 rpm shaking. After the treatment, surviving persister 
cells were washed twice with PBS buffer to remove any remaining antibiotic. The collected cells 
were resuspended in PBS plated to determine the viability by counting CFU as described 
previously. 
 
4.2.5 Erythromycin accumulation of persister cells 
 
To verify if persister cells did accumulate more erythromycin than normal cells, we conducted an 
experiment to treat the cells with erythromycin first and compared the antimicrobial activities of 
the lysates from these cells. We also directly measured the intracellular concentration of 
erythromycin using mass spectrophotometry (MS).  
Briefly persister cells were isolated from exponential cultures of E. coli HM22 by treating with 
100µg/mL Amp for 3.5 hours to kill normal cells. The CFU of normal and persister cell culture 
samples were normalized based on OD600 readings. Both samples were treated with 100 µg/mL 
erythromycin in PBS for 10 minutes. Then cells were collected by centrifugation and supernatant 
samples were stored at -20˚C till MS analysis and killing experiment. The cell pellets were 
sonicated (5 cycles at 100% amplitude with 30 s treatment for each cycle in ice-water) and 
pipetted up and down to disrupt the cell membrane. Then, cell lysates were filtered through 0.2 
µm filters and sent for MS analysis to Dr. Myriam Cotton at Hamilton College, Clinton, NY.  A 
13C labeled erythromycin was used as an internal standard to verify the molecular weight of 
erythromycin used in this study. The samples were also tested on fresh planktonic cultures of E. 
coli HM22 for their killing activity and compared to that of 50 µg/ml erythromycin. 
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4.3 Results  
 
4.3.1 Efflux activity of normal and persister cells 
 
The induction of persister formation with arabinose was successful and the persister population 
was 0.16% in uninduced sample, and 17% with induction with arabinose and Tet.  The isolated 
persister cells were treated with EtBr solution to see if persister cells could accumulate more 
EtBr intracellularly due to lower activity of efflux pumps. As expected, it was found that the 
induced sample had 29.9±1.6% more EtBr signal than uninduced sample after 10 minutes of 
incubation (Fig. 4-2).   
 
Figure 4-2. Ratios of EtBr signal of induced cells / uninduced cells. EtBr signals were measured 
using a fluorescence microplate reader (model FLx800, Bio-Tek Instruments, Winooski, VT, 
USA) with excitation at 360 nm. The ratios; 1.12±0.8%, 24.3±3.2%, 29.9±1.6%, and  18.9±1.5% 
at 0, 5, 10, and 30 minutes after adding EtBr are shown.  
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4.3.2 Flow cytometry analysis of efflux activity with EtBr staining  
 
The results show that adding EtBr caused E. coli ΔacrB cells, which have no efflux activity, to 
shift from low red fluorescence (less than 103) to high red fluorescence area (higher than 103) 
(Fig. 4-3). This finding proves that EtBr accumulates inside the cells if the efflux activity is not 
present, and demonstrates that flow cytometry analysis with EtBr staining is effective in 
membrane potential studies.  
 
  
 
 
Figure 4-3. Flow cytometry data showing fluorescent signals of unstained and EtBr stained E. 
coli ΔacrB cells. The cells were analyzed for their green (FL1) and red (FL2) fluorescence. A1) 
and A2) are unstained samples while, B1) and B2) are EtBr stained samples. 
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4.3.3 Persister induction  
 
E. coli Top10 pBAD hipA (Fig 4-4 A1 and 4-4 A2) cells that were not induced for persister 
formation did not show significant fluorescent signal after incubation with EtBr for 10 min (Fig. 
4-4 B1 and 4-4 B2). In contrast, 13% of the cells in arabinose induced sample (circled with red 
dotted line) showed more than 10 fold higher red fluorescent signal than the rest of the 
population and uninduced cells. Consistently, 18% of cells in this sample were confined to be 
persister cells based on CFU results. This finding shows that the persister population of E. coli 
Top10 pBAD hipA strain has lower efflux activity compared to normal cells, which is consistent 
with the results of E. coli ΔacrB efflux mutant. Since the efflux pump activity depends on 
membrane potential, these results suggest that persister cells have lower membrane potential than 
normal cells.  
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Figure 4-4. Persister formation led to increase in intracellular concentration of EtBr. A1 and A2; 
no induction and no staining, B1 and B2; without induction of persister formation, but with EtBr 
staining, C1 and C2; with induction of persister formation and EtBr staining. E. coli Top10 
pBAD hipA was used in all the tests. 
 
In addition to high level persistence strain, E. coli ASV which only has around 0.1% persister 
ratio was also tested with flow cytometry for their dim color compared to green active 
exponential cells with no staining. This small number of persister cells showed up as a distinct 
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population plot in cytometry analysis (Fig. 4-5). This strain is only green when the cells are 
active, and persister cells did not show any green color. 
 
 
 
Figure 4-5. Flow cytometry analysis of E. coli ASV strain. Red circle shows the dim persister 
population.  
 
4.3.4  Comparing membrane potential of persister and normal cells with potentiometric 
dye and flow cytometry 
 
We further tested membrane potential using, E. coli Top10 pBAD hipA with and without the 
induction of persister formation with 0.2% arabinose. Fig. 4-6 shows that the induced persister 
formation led to decrease in red fluorescence, while the level of green fluorescence (stains all 
cells) did not change. This reduced level of red fluorescent suggest that less JC-1 dye molecules 
accumulated on the membrane due to lower membrane potential.   
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Figure 4-6. Potentiometric staining and flow cytometry results of uninduced (A1-A3) and 
induced (B1-B3) E. coli Top10 pBAD hipA cells. A2) and B2) show the signal of green 
fluorescence while A3) and B3) show the signal of red fluorescence.  
 
 
4.3.5 Activity of efflux substrate antibiotics on persister cells  
 
Among tested antibiotics 50µg/ml erythromycin killed 78.2% of E. coli HM22 persister cells 
after 3 h (Fig. 4-7B) while the same concentration has less than 30% killing on normal cells (Fig. 
4-7A). This higher killing effect of erythromycin on persister cells could only be repeated when 
PBS is used as washing and treatment buffer. This indicates presence of some ions helped 
erythromycin effect to kill persister cells.  
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Figure 4-7. Effects of erythromycin on the viability of E. coli normal (A) and persister (B) cells. 
The number of cells before treatment was normalized as 100%.  
 
4.3.6 Intracellular accumulation of erythromycin  
 
As shown in Fig. 4-8, lysate from erythromycin treated persister cells exhibited higher killing 
activity on E. coli HM22 cells than that from erythromycin treated normal cells. As negative 
controls, cell lysates without pretreatment with erythromycin did not cause any significant 
change in cell viability (less than 4%). The killing by the lysate of persister cells treated with 
erythromycin pellet was 18.1 ± 3.6%, similar to while it was 19.4 ± 4.7% by adding 50 µg/mL 
erythromycin directly. This suggests that persister cells accumulated a high concentration of 
erythromycin.   
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Figure 4-8. Antimicrobial effects of cell lysates from erythromycin treated normal & persister 
cells of E. coli HM22. NC; normal cells, PC; persister cells. In total 8 types of samples were 
tested; NExEr (normal cells extracellular erythromycin, Fig. 4-9), NInEr (normal cells 
intracellular erythromycin, Fig. 4-10), PExEr (persister cells extracellular eryhtromycin, Fig. 4-
11), PInEr (persister cells intracellular eryhtromycin, Fig. 4-12), NEx13 (normal cells 
extracellular 13C labeled eryhtromycin, Fig 4-13), NIn13 (normal cells intracellular 13C labeled 
eryhtromycin, Fig 4-14), PEx13 (persister cells extracellular 13C labeled eryhtromycin, Fig 4-15), 
PIn3 (persister cells intracellular 13C labeled erythromycin, Fig 4-16). 
 
Consistent with the CFU results, MS analysis revealed that persister cell pellet had relatively 
higher erythromycin accumulation compared to normal cells. As shown in Table 4-2, the 
extracellular erythromycin levels were significantly higher (at least 14 fold) than the intracellular 
erythromycin level in normal cells. This result confirmed that normal cells can actively pump out 
erythromycin. In contrast, this ratio becomes much lower (1.6) for persister cells (8.7 fold 
decrease). This finding suggests that persister cells can not actively pump the erythromycin out.  
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Figure 4-9. Mass Spectrophotometry analysis of erythromycin level in the extracellular 
supernatant of normal cell samples 
 
 
Figure 4-10. Mass Spectrophotometry analysis of intracellular erythromycin level in normal cell 
samples  
 
 
Figure 4-11. Mass Spectrophotometry analysis of erythromycin level in the extracellular 
supernatant of persister cell samples 
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Figure 4-12. Mass Spectrophotometry analysis of intracellular erythromycin level in persister 
cell samples  
 
 
Figure 4-13. Mass Spectrophotometry analysis of 13C labeled erythromycin level in the 
extracellular supernatant of normal cell samples.  
 
 
Figure 4-14. Mass Spectrophotometry analysis of intracellular 13C labeled erythromycin level in 
normal cell samples  
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Figure 4-15. Mass Spectrophotometry analysis of 13C labeled erythromycin level in the 
extracellular supernatant of persister cell samples 
 
 
Figure 4-16. Mass Spectrophotometry analysis of intracellular 13C labeled erythromycin level in 
persister cell samples  
 
Table 4-2. Ratios of intracellular vs extracellular concentration of erythromycin. The 
concentrations were determined using MS analysis. 
Relative ratio between Value (fold) 
NExEr/NInEr 30.2 
NEx13/NIn13 14  
PExEr/PInE 1.4 
PEx13/PIn13 1.6 
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4.4 Discussion 
 
Normal E. coli cells pump EtBr out by AcrAB-TolC efflux pumps [42]. Erythromycin is also a 
substrate of this efflux pump [18]. Consistently E. coli ΔacrB, which has a nonfunctional 
AcrAB-TolC pump, showed high level of EtBr accumulation in flow cytometry experiments 
(Fig. 4-3B1, 4-3B2). 
Having more EtBr accumulation in persister cells (Fig 4-2) suggests that persister formation does 
cause lower efflux activities since inactive efflux pumps cannot extrude EtBr.  The slight 
decrease in decrease in signal level after 10 minutes can be explained by cell damage or death 
due to the toxic effects of prolonged EtBr treatment on E. coli cells [43].  
Since the frequency of persister formation is generally low [2], we tested with a high persistence 
strain, E. coli Top10 pBAD hipA, using flow cytometry to determine efflux activities of persister 
cells. As seen in Fig. 4-4, EtBr signals of the population shifted to red fluorescence and a 
population of persister cells was distinguished with even higher red signal. These data also 
support the low efflux activities in persister cells, as a result of dormant nature of persister cells.  
These efflux activity results were corroborated with a potentiometric dye, JC-1, which can 
directly label the potential of a cell membrane [44,45]. When the arabinose induced E. coli 
Top10 pBAD hipA was stained with JC-1 dye and analyzed using flow cytometry, a small 
subpopulation with low red color was detected. The amount of cells in this population correlates 
well with the persistence level, further support that persister cells have lower membrane 
potentials than normal cells.  
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In parallel to membrane potential experiments, we also studied the effect of some ribosome 
targeting antibiotics, which are also the substrates of the AcrAB-TolC pump efflux system [18], 
[33]. Erythromycin, tetracycline and chloramphenicol are all substrates of E. coli AcrAB-TolC 
pumps [18, 33-36]. Because persister cells have reduced membrane potential & efflux activity, 
we expect these antibiotics can accumulate more intracellularly in persister cells. Interestingly, 
erythromycin showed higher killing effect on persister cells than normal cells. Since efflux pump 
activity is essential for the resistance to erythromycin [46], we speculated that this higher killing 
activity against persister cells may be caused by inactive efflux pumps due to low membrane 
potential of these cells which led to accumulation of more erythromycin molecules in persister 
cells.  
It has been reported that tetracycline uptake occurs with both energy dependent and independent 
mechanisms [47]. E. coli cells in exponential cultures are susceptible to tetracyline while the 
persister cells are tolerant. This energy dependent cellular uptake of tetracycline might explain 
why normal cells are more susceptible compared to dormant persister cells, which is different 
from the results of erythromycin.  
As illustrated in Fig. 4-17, erythromycin molecules diffuse into the cells [48], regardless of the 
metabolic stage. This antibiotic kills bacterial cells by binding to ribosomal complex and 
inhibiting protein synthesis [49]. In active cells, efflux proteins can pump erythromycin out 
before they reach and bind to the target. Persister cells have lower membrane potential, and thus 
inactivate efflux systems. Therefore more erythromycin will accumulate in the cells and target 
the ribosome complex during wakeup (on agar plates), leading to bacterial killing.  
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Figure 4-17. Schematic of possible effects of erythromycin on normal (A) and persister (B) cells  
 
Normally E. coli is resistance to erythromycin and susceptible to tetracycline. However, we have 
observed higher killing with erythromycin on E. coli persister cells while the cells were not 
affected with tetracycline treatment. Erythromycin is a bacteriostatic antibiotic [50] which means 
it requires bacterial activity to inhibit and eventually kill the bacteria. The activity of 
erythromycin also requires the presence of K+ ions for binding to ribosome [49,51,52]. 
Consistently, when 0.85% NaCl solution rather than PBS was used to wash the cells, persister 
killing by erythromycin was not observed. Erythromycin forms a very stable complex with its 
target ribosome. The dissociation constant of eryhtromycin and ribosomes is between 1.1x10-7 
and 3.4x10-7 M [53]. In comparison, the dissociation constant between tetracycline and its target 
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is 1x10-6 [54], a magnitude higher than erythromycin. Collectively, the differences in binding 
strength may explain why the other two antibiotics did not show similar effects as eryhtromycin 
since their diffusion is faster than wake up upon removal of antibiotics.  
In the case of chloramphenicol, the binding is even weaker than tetracycline; e.g; the dissociation 
constant is 2x10-6 [55]. Besides, chloramphenicol uptake by Gram negative bacteria is suggested 
by means of an energy-dependent processes [56]. These two reasons might explain why 
chloramphenicol could not show killing effect on persister cells. These results revealed that there 
are weaknesses of persister cells, which can be targeted by antimicrobials to achieve killing of 
this dormant population.  
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CHAPTER 5 
 
NEW AMP DERIVATIVES OF CALCITERMIN AND THEIR EFFECTS ON 
PSEUDOMONAS AERUGINOSA and ESHERICHIA COLI  
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5.1 Introduction 
 
The growing interest in AMPs, also defined as natural microbicidals [1],  as alternative 
antimicrobial agents to current antibiotics is also favored by their low propensity to induce drug 
resistance [2]. Native AMPs can serve as a source of antimicrobial agents for treatment of 
different infectious diseases. However, clinical use of native AMPs have issues such as potential 
toxicity to human cells and proteolytic degradation. Thus many studies have been conducting to 
search for better AMPs by re-designing native antimicrobial peptides recently [3]. For example, 
dermicidin secreted from epihelia can be further improved by removing 23 amino acid from N-
terminal end to have 2-fold increase in killing activity against E. coli [4] and this new derivative 
of dermicidin can be more effective in skin infections. This will also adress concerns related to 
the stability of AMPs. Efforts have also been made to generate and screen AMP libraries based 
on native AMPs to study a large number of candidates simultaneously. This allows identification 
of important features in AMP structures and physiochemical properties required for specific 
activities of AMPs [1]. 
AMPs from different sources identified to date have provided important information for 
designing new sythetic AMPs with improved antimicrobial effects, target spectrums, and 
stabilities under different physiological conditions along with reduced cost due to short amino 
acid sequences [3].  
We hypothesized that some human originated natural AMPs can be further improved to kill 
bacterial persister cells by and optimizing their physiochemical characteristics. Specifically, we 
studied the effects of the net charge of an AMP on planktonic & persister cells of E. coli and P. 
aeruginosa.  
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Among these AMPs we selected calcitermin, which has 15 amino acid in length with a net 
charge of “+1” and an α-helical structure [5], to study the effects of AMP net-charge on the 
persister cells of P. aeruginosa PAO1 (from cystic fibrosis patients) and E. coli HM22. The 
antimicrobial effects of native calcitermin on E. coli and P. aeruginosa has been reported 
previously [6] and its short length is considered a favorable characteristics for low cost 
manufacturing.  
Both the amino acid sequence and local pH can affect the net charge of an AMP [7]. Therefore 
by adding more negatively charged amino acids into the sequence of calcitermin, we designed 
neutral and negatively charged calcitermin derivatives with the help of Iterative Threading 
ASSEmbly Refinement (I-TASSER) Protein Structure & Function Predictions which is available 
online [8].  
 
5.2 Materials and Methods 
 
5.2.1 Selecting the candidate AMP to study  
 
To choose the AMP, 277 human originated AMPs chosen from two antimicrobial peptide 
databases, Antimicrobial Peptide Database (APD2) and Linking Antimicrobial Peptide (LAMP) 
which has 5547 AMPs in total, were compared for their given physiochemical characteristics. 
Human originated peptides were selected to minimize cytotoxicity in human body. Some of these 
AMPs are shown in (Table 5-1). Calcitermin was selected due to its short size (low production 
cost), relatively high hydrophobicity (for amphipathic structure and antimicrobial activity), 
relatively low boman index (for less interaction with other proteins), positive charge, origin 
tissue (airway secretions), and ɑ-helical structure which is important to target cell membrane.  
  
Table 5-1. Selected human originated AMPs with some of their important physiochemical characteristics, sources in the body and 
activities. The data is collected from APD2 and LAMP libraries. G(+); Gram positive bacteria, G(-); Gram negative bacteria. 
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AP00309 KS-27 Skin KSKEKIGKEFKRIVQRIKDFLRNLVPR 27 7 33% 3.38 Unknown G(+), G(-), 
AP00481 Kaliocin-1 Lactoferrin  FFSASCVPGADKGQFPNLCRLCAGTGENKCA 31 1 45% 0.99 Unknown N/A 
AP00625 KR-20  Sweat KRIVQRIKDFLRNLVPRTES 20 4 35% 3.68 Helix G(+), G(-), Antifungal, 
AP00626 KS-30  Sweat KSKEKIGKEFKRIVQRIKDFLRNLVPRTES 30 6 30% 3.47 Helix G(+), G(-), 
AP00627 RK-31 Sweat RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 31 7 29% 3.83 Helix G(+), G(-), Antifungal,  
AP00628 LL-23  Skin LLGDFFRKSKEKIGKEFKRIVQR 23 5 34% 3.01 Helix G(+), G(-), Antifungal, 
AP00629 LL-29  Skin LLGDFFRKSKEKIGKEFKRIVQRIKDFLR 29 6 37% 2.95 Helix G(+), G(-), 
AP00765 Salvic Saliva MHDFWVLWVLLEYIYNSACSVLSATSSVSSRVLNRSLQVKVVKITN 46 2 50% 0.7 Unknown N/A 
AP00798 Hst1 Saliva DSHEKRHHGYRRKFHEKHHSHREFPFYGDYGSNYLYDN 38 0 10% 4.29 H Rich Antifungal 
AP00799 Histatin 2 Saliva RKFHEKHHSHREFPFYGDYGSNYLYDN 27 0 14% 3.53 H Rich Antifungal 
AP00801 Histatin 6  Saliva DSHAKRHHGYKRKFHEKHHSHRGYR 25 6 8% 5.21 H Rich G(+), G(-), Antifungal, 
AP00802 Histatin 7 Saliva RKFHEKHHSHRGY 13 3 7% 5.07 H Rich Antifungal 
AP00803 Histatin 9 Saliva RKFHEKHHSHRGYR 14 4 7% 5.78 H Rich G(+), G(-), Antifungal, 
AP01407 SgI-29  Sperm HNKQEGRDHDKSKGHFHRVVIHHKGGKAH 29 4 17% 3.74 H Rich G(+), G(-), 
AP02017 hGAPDH Placenta  GKVKVGVNGFGRIGRLVTRAAFNSGKVDIVA 31 5 45% 1.07 Unknown Antifungal 
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AP02230 HMGN2 Leukocyte 
PKRKAEGDAKGDKAKVKDEPQRRSARLSAKPAPP
KPEPKPKKAPAKKGEKVPKGKKGKADAGKEGNNP
AENGDAKTDQAQKAEGAGDAK 
89 12 21% 3.2 Unknown G(-), Antifungal, Antiviral 
AP02343 Beta 2-globulin Amnio 
IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIE
VDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTP
TEKDEYACRVNHVTLSQPKIVKWDRDM 
99 -2 31% 2.31 Beta G(+), G(-), 
AP00176 Neutrophil peptide-1 Neutrophil 
ACYCRIPACIAGERRYGTCIYQGRLWAFCC 30 3 53% 1.07 Beta 
G(+), G(-), 
Antiviral, 
Antifungal, 
Antiparasitic, 
Cancer cells 
AP00179 Neutrophil peptide-4 Neutrophil 
VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV 33 4 51% 1.4 Beta 
G(+), G(-), 
Antiviral, 
Antifungal,  
AP00180 Defensin 5 Skin  ATCYCRTGRCATRESLSGVCEISGRLYRLCCR 32 4 40% 2.6 Beta G(+), G(-), Antifungal 
AP00181 Defensin 6 Skin AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL 32 2 40% 1.71 Beta Antiviral, Antifungal, 
AP00192 Hepcidin 20 Blood  ICIFCCGCCHRSKCGMCCKT 20 3 60% 0.46 Beta Antifungal, 
AP00193 LEAP-1  Liver DTHFPICIFCCGCCHRSKCGMCCKT 25 2 52% 0.89 Beta G(+), G(-), Antifungal 
AP00196 hBD-26  Skin WYVKKCLNDVGICKKKCKPEEMHVKNGWAMCGKGRDCCVPAD 42 4 42% 1.58 Bridge G(-), 
AP00197 hBD-27  Skin QLKKCWNNYVQGHCRKICRVNEVPEALCENGRYCCLNIKELEAC 44 2 43% 2.08 Bridge G(-), 
AP00283 Beta defensin 3  Skin 
GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTR
GRKCCRRKK 45 11 33% 2.87 
Helix and 
beta 
G(+), G(-), 
Antiviral, 
Antifungal, 
Chemotactic, 
AP00307 Buforin I  Stomach AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY 39 12 28% 3.08 Unknown 
G(+), G(-), 
Antifungal 
AP00310 LL-37,  
Neutrophil 
skin, sweat, 
lung,  
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 37 6 35% 2.99 Helix 
G(+), G(-), 
Antiviral, 
Antifungal, 
Antiparasitic, 
Spermicidal, 
Chemotactic, 
Cancer cells 
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AP00334 Cathepsin  Neutrophil  IIGGR 5 1 40% 0.64 Unknown G(+), G(-), 
AP00433 Dermicidin  Sweat SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSV 47 -2 38% 1.11 Helix 
G(+), G(-), 
Antifungal 
AP00449 MSH Brain SYSMEHFRWGKPV 13 1 30% 2.01 Unknown 
G(+), 
Antifungal, 
Antiviral,  
AP00451 hBD-1  
Keratinocyte 
skin, 
platelets 
DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCC
K 36 4 36% 1.3 
Helix and 
beta 
G(+), G(-), 
Antiviral, Cancer 
cells 
AP00504 MUC7 20  Saliva  LAHQKPFIRKSYKCLHKRCR 20 7 35% 3.16 Helix G(+), G(-), Antifungal 
AP00505 Histatin 5  Parotid secretion 
DSHAKRHHGYKRKFHEKHHSHRGY 24 5 8% 4.81 Helix,  H-rich 
G(+), G(-), 
Antiviral, 
Antifungal, 
Enzyme 
inhibitor 
AP00509 Calcitermin Airways secretions 
VAIALKAAHYHTHKE 15 1 46% 0.89 Helix G(-), Antifungal 
AP00520 Histatin 3,  
Saliva, 
parotid 
secretion 
DSHAKRHHGYKRKFHEKHHSHRGYRSNYLYDN 32 5 9% 4.72 H-rich G(+), G(-), Antifungal 
AP00523 Histatin 8 Saliva KFHEKHHSHRGY 12 2 8% 4.25 H-rich G(+), G(-), Antifungal 
AP00524 Defensin 2 
Skin, lung, 
trachea 
epithelia, 
and uterus, 
GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTK
CCKKP 41 7 36% 0.9 
Helix and 
beta 
G(+), G(-), 
Antiviral, 
Antifungal, 
Chemotactic, 
AP00624 ALL-38,  Sperm ALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 38 6 36% 2.87 Helix G(+), G(-), 
AP00800 Histatin 4,  Saliva RKFHEKHHSHRGYRSNYLYDN 21 3 9% 4.84 H-rich Antifungal, 
AP00675 Defensin 4,  Skin FELDRICGYGTARCRKKCRSQEYRIGRCPNTYACCLRKWDESLLNRTKP 49 7 32% 3.35 bridge G(+), G(-), 
AP00780 lactoferricin Lactoferrin GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA 49 10 36% 3.14 Helix G(+), G(-), 
AP00811 LEAP-2  Liver MTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLSVAQE 40 4 40% 2.94 
Helix and 
beta 
G(+), G(-), 
Antifungal 
AP00833 Drosomycin  Skin CLAGRLDKQCTCRRSQPSRRSGHEVGRPSPHCGPSRQCGCHMD 43 5 25% 3.58 Bridge Antifungal, 
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AP00857 Catestatin,  Brain  SSMKLSFRARAYGFRGPGPQL 21 4 33% 1.98 Unknown 
G(+), G(-), 
Antifungal, 
Chemotactic, 
Antioxidant, 
AP01161 Granulysin,  Cytolytic t cells  
GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVC
RTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQ
ICEDLR 
74 11 33% 3.5 Helix 
G(+), G(-), 
Antifungal, 
Antiparasitic, 
Cancer cells 
AP01315 hBD-28  Skin ARLKKCFNKVTGYCRKKCKVGERYEIGCLSGKLCCAN 37 8 40% 1.91 Beta G(+), G(-), 
AP01372 CXCL14,  N/A 
SKCKCSRKGPKIRYSDVKKLEMKPKYPHCEEKMVI
ITTKSVSRYRGQEHCLHPKLQSTKRFIKWYNAWNE
KRRVYEE 
77 13 27% 3.03 Unknown G(+), G(-), Antifungal 
P01373 TC-1  Blood AELRCMCIKTTSGIHPKNIQSLEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKKIVQKKLAGDES 68 6 38% 1.72 
Helix and 
Beta 
structure 
G(+), G(-), 
Antifungal 
AP01374 TC-2  Blood 
NLAKGKEESLDSDLYAELRCMCIKTTSGIHPKNIQS
LEVIGKGTHCNQVEVIATLKDGRKICLDPDAPRIKK
IVQKKLAGDES 
83 2 36% 1.87 Unknown G(+), G(-), Antifungal 
AP01408 SgII  Sperm KQEGRDHDKSKGHFHMIVIHHKGGQAHHG 29 2 20% 2.85 H-Rich G(+), G(-), 
AP01471 Substance P Blood RPKPQQFFGLM 11 1 36% 1.57 Helix G(+), G(-), Antifungal 
AP01472 Neurotensin,  Brain ELYENKPRRPYIL 13 3 23% 3.16 Unknown G(+), G(-), Antifungal 
AP01473 Bradykinin  Brain RPPGFSPFR 9 2 22% 2.92 Unknown G(+), G(-), Antifungal 
AP01474 Neuropeptide Y Brain YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY 36 1 25% 3 Helix 
G(+), G(-), 
Antifungal 
AP01475 DEFB120  
Pooled 
fetal lung, 
testis, b-
cell 
ECWMDGHCRLLCKDGEDSIIRCRNRKRCC 29 2 41% 3.66 Bridge G(+), G(-), Antifungal 
AP01476 Calcitonin  Thyroid ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF 37 4 43% 1.08 Helix G(-), Antifungal 
AP01477 Vasoactive polypeptide  Intestine 
HSDAVFTDNYTRLRKQMAVKKYLNSILN 28 4 35% 2.48 Unknown G(+), G(-), Antifungal 
AP01479 Adrenomedullin  Skin YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY 52 6 28% 2.6 Helix G(+), G(-), 
AP01494 GHH20  Skin GHHPHGHHPHGHHPHGHHHPH 21 0 0% 2.7 H-Rich Antifungal, 
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AP02071 TCP   Skin 
NLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGD
ACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDR
DGKYGFYTHVFRLKKWIQKVIDQFGE 
96 2 33% 2.15 Unknown G(+), G(-), 
AP02072 Elafin  Skin AQEPVKGPVSTKPGSCPIILIRCAMLNPPNRCLKDTDCPGIKKCCEGSCGMACFVPQ 57 3 42% 0.94 Beta 
G(+), G(-), 
Antiviral, 
Antifungal, 
Enzyme 
inhibitor 
AP02073 Abeta40 Brain  DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 40 -3 42% 0.98 Helix 
G(+), G(-), 
Antiviral, 
Antifungal 
AP02075 Abeta42 Brain DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA 42 -3 45% 0.77 Helix 
G(+), G(-), 
Antiviral, 
Antifungal 
AP02076 RNase 5  
Liver, 
intestine, 
skin 
QDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGP
TSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRIS
KSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVA
CENGLPVHLDQSIFRRPRP 
125 11 28% 2.99 
Helix and 
Beta 
structure 
G(+), Antifungal 
AP02077 RegIII alpha  Islets, intestine 
EEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWT
DADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNS
YSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFA
WERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLP
YVCKFTD 
149 1 33% 1.77 
Helix and 
Beta 
structure 
G(+), 
AP02078 Psoriasin  Skin, tounge 
MSNTQAERSIIGMIDMFHKYTRRDDKIDKPSLLTM
MKENFPNFLSACDKKGTNYLADVFEKKDKNEDKK
IDFSEFLSLLGDIATDYHKQSHGAAPCSGGSQ 
101 -1 32% 2.3 Helix G(-), Chemotactic 
AP02079 RNase 7  
Skin, 
urinary 
tract 
KPKGMTSSQWFKIQHMQPSPQACNSAMKNINKHT
KRCKDLNTFLHEPFSSVAATCQTPKIACKNGDKNC
HQSHGAVSLTMCKLTSGKYPNCRYKEKRQNKSYV
VACKPPQKKDSQQFHLVPVHLDRVL 
128 16 32% 2.16 
Helix and 
Beta 
structure 
G(+), G(-), 
Antifungal 
AP02080 CCL20  Skin SNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM 69 8 43% 1.34 
Helix and 
Beta 
structure 
G(+), G(-), 
Antifungal, 
Antiparasitic,  
AP02081 CXCL1  Bone marrow 
ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCA
QTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKS
N 
73 6 38% 1.51 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02082 CXCL2 
Bone 
marrow 
APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCA
QTEVIATLKNGQKACLNPASPMVKKIIEKMLKNGK
SN 
73 8 39% 1.17 
Helix and 
Beta 
structure 
G(+), G(-), 
Antiparasitic, 
Chemotactic, 
AP02083 CXCL3  
Bone 
marrow 
ASVVTELRCQCLQTLQGIHLKNIQSVNVRSPGPHCA
QTEVIATLKNGKKACLNPASPMVQKIIEKILNKGST
N 
73 6 39% 1.27 Unknown G(+), G(-), Chemotactic 
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AP02084 CXCL9  
Bone 
marrow 
TPVVRKGRCSCISTNQGTIHLQSLKDLKQFAPSPSCE
KIEIIATLKNGVQTCLNPDSADVKELIKKWEKQVSQ
KKKQKNGKKHQKKKVLKVRKSQRSRQKKTT 
103 20 28% 2.7 Unknown 
G(+), G(-), 
Antiparasitic, 
Chemotactic, 
AP02085 CXCL10  
Bone 
marrow 
VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPR
VEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSK
RSP 
77 11 36% 2.25 
Helix and 
Beta 
structure 
G(+), G(-), 
Antifungal, 
Antiparasitic, 
AP02086 CXCL11 
Bone 
marrow 
FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNN
CDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKN
F 
73 11 41% 1.83 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02087 CXCL12 Stomach  KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK 68 9 42% 1.93 
Helix and 
Beta 
structure 
G(+), G(-), 
Antiviral 
AP02088 CXCL13  Stomach 
VLEVYYTSLRCRCVQESSVFIPRRFIDRIQILPRGNG
CPRKEIIVWKKNKSIVCVDPQAEWIQRMMEVLRKR
SSSTLPVPVFKRKIP 
87 11 41% 2.1 Unknown G(+), G(-), Chemotactic 
AP02089 XCL1  Stomach 
VGSEVSDKRTCVSLTTQRLPVSRIKTYTITEGSLRA
VIFITKRGLKVCADPQATWVRDVVRSMDRKSNTR
NNMIQTKPTGTQQSTNTAVTLTG 
93 9 32% 2.41 Beta G(+), G(-), Chemotactic 
AP02090 I-309,  Lymphocyte 
KSMQVPFSRCCFSFAEQEIPLRAILCYRNTSSICSNE
GLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSK
RK 
73 10 41% 2.25 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02091 MCP-2,  Macrophage  
PDSVSIPITCCFNVINRKIPIQRLESYTRITNIQCPKEA
VIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNL
KP 
75 6 37% 2.27 
Helix and 
Beta 
structure 
G(-), 
Chemotactic 
AP02092 Eotaxin,  Eosinophil  
GPASVPTTCCFNLANRKIPLQRLESYRRITSGKCPQ
KAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSP
TPKP 
74 11 33% 2.03 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02093 MCP-4,  Macrophage 
QPDALNVPSTCCFTFSSKKISLQRLKSYVITTSRCPQ
KAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAH
TLKT 
75 11 36% 1.89 
Helix and 
Beta 
structure 
G(-), 
Chemotactic 
AP02094 TARC,  Platelet 
ARGTNVGRECCLEYFKGAIPLRKLKTWYQTSEDCS
RDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLER
S 
71 6 36% 2.42 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02095 PARC,  Platelet AQVGTNKELCCLVYTSWQIPQKFIVDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA 69 5 37% 1.39 Unknown 
G(+), G(-), 
Chemotactic 
AP02096 MIP-3 Leukocyte 
 
GTNDAEDCCLSVTQKPIPGYIVRNFHYLLIKDGCRV
PAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAK
MKRRSS 
 
77 7 37% 2.23 Unknown G(-), Chemotactic 
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AP02097 TECK,  Leukocyte 
QGVFEDCCLAYHYPIGWAVLRRAWTYRIQEVSGSC
NLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDAR
NKVFAKLHHNTQTFQAGPHAVKKLSSGNSKLSSSK
FSNPISSSKRNVSLLISANSGL 
127 15 37% 1.81 Unknown G(+), G(-), Chemotactic 
AP02099 SLC,  Leukocyte 
SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSI
PAILFLPRKRSQAELCADPKELWVQQLMQHLDKTP
SPQKPAQGCRKDRGASKTGKKGKGSKGCKRTERS
QTPKGP 
111 16 27% 2.65 
Helix and 
Beta 
structure 
G(+), G(-), 
Chemotactic 
AP02158 MDC,  Leukocyte GPYGANMEDSVCCRDYVRYRLPLRVVKHFYWTSDSCPRPGVVLLTFRDKEICADPRVPWVKMILNKLSQ 69 4 40% 1.85 Unknown 
G(+), G(-), 
Chemotactic 
AP02182 SLPI  Saliva,  Airway 
SGKSFKAGVCPPKKSAQCLRYKKPECQSDWQCPG
KKRCCPDTCGIKCLDPVDTPNPTRRKPGKCPVTYG
QCLMLNPPNFCEMDGQCKRDLKCCMGMCGKSCV
SPVKA 
107 12 34% 1.87 Beta 
G(+), G(-), 
Antiviral, 
Antifungal, 
Enzyme 
inhibitor, 
AP02184 UBI 1-59 Small intestine 
KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAK
RRMQYNRRFVNVVPTFGKKKGPNANS 59 19 25% 3.28 Unknown G(+), G(-), 
AP02185 RNase 8  Urinary tract 
KPKDMTSSQWFKTQHVQPSPQACNSAMSIINKYTE
RCKDLNTFLHEPFSSVAITCQTPNIACKNSCKNCHQ
SHGPMSLTMGELTSGKYPNCRYKEKHLNTPYIVAC
DPPQQGDPGYPLVPVHLDKVV 
127 4 31% 1.7 Unknown G(+), G(-), Antifungal 
AP02186 ECP  Eosinophilic leukocytes 
RPPQFTRAQWFAIQHISLNPPRCTIAMRAINNYRWR
CKNQNTFLRTTFANVVNVCGNQSIRCPHNRTLNNC
HRSRFRVPLLHCDLINPGAQNISNCTYADRPGRRFY
VVACDNRDPRDSPRYPVVPVHLDTTI 
133 13 36% 2.71 
Helix and 
Beta 
structure 
G(+), G(-), 
Antiviral, 
Antiparasitic, 
Mammalian 
cells, 
AP02187 hPF4  Platelet EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES 70 3 40% 1.46 Unknown 
Antiparasitic, 
Antimalarial, 
AP02195 DEFB114  Gingival cells  
DRCTKRYGRCKRDCLESEKQIDICSLPRKICCTEKL
YEEDDMF 43 0 32% 3.58 Bridge 
G(+), G(-), 
Antifungal 
AP02196 Alarin   Brain APAHRSSTFPKWVTKTERGRQPLRS 25 5 24% 3.47 Unknown G(-), 
AP02231 CXCL6  Bone marrow 
GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGP
QCSKVEVVASLKNGKQVCLDPEAPFLKKVIQKILD
SGNKKN 
77 8 41% 1.14 Unknown 
G(+), G(-),  
Antiparasitic, 
Chemotactic, 
AP02257 Kinocidin 
Saliva, 
milk, 
epithelial 
cells/mucos
al tissues 
MQQRGLAIVALAVCAALHASEAILPIASSCCTEVSH
HISRRLLERVNMCRIQRADGDCDLAAVILHVKRRRI
CVSPHNHTVKQWMKVQAAKKNGKGNVCHRKKH
HGKRNSNRAHQGKHETYGHKTPY 
127 16 39% 2.3 Unknown 
G(+), G(-),  
Antifungal, 
Antiparasitic, 
Chemotactic, 
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AP02337 CCL27  Brain  PPSTACCTQLYRKPLSDKLLRKVIQVELQEADGDCHLQAFVLHLAQRSICIHPQNP 56 1 41% 1.57 
Helix and 
Beta 
structure 
Antifungal, 
Chemotactic 
AP02409 Chemerin  Epidermis, skin,  
ELTEAQRRGLQVALEEFHKHPPVQWAFQETSVESA
VDTPFPAGIFVRLEFKLQQTSCRKRDWKKPECKVR
PNGRKRKCLACIKLGSEDKVLGRLVHCPIETQVLRE
AEEHQETQCLRVQRAGEDPHSFYFPGQFAFS 
137 3 36% 2.38 Unknown 
G(+), G(-),  
Antifungal, 
Chemotactic, 
AP02425 hIAPP,  Islets  KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 37 3 37% 1.48 Helix G(+), G(-), 
AP02451 KDAMP 10 Cornea  RAIGGGLSSVGGGSSTIKY 19 2 26% 0.55 Unknown G(-), 
AP02452 Lysozyme  Secretions and tissues 
KVFERCELARTLKRLGMDGYRGISLANWMCLAKW
ESGYNTRATNYNAGDRSTDYGIFQINSRYWCNDGK
TPGAVNACHLSCSALLQDNIADAVACAKRVVRDP
QGIRAWVAWRNRCQNRDVRQYVQGCGV 
130 8 40% 2.28 Helix G(+), G(-), Antifungal 
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5.2.2 Designing new calcitermin derivatives with different net charges 
 
We used I-TASSER to design neutral and negatively charged derivatives of calcitermin based on 
the original amino acid sequence; VAIALKAAHYHTHKE. This prediction method helped us to 
keep α-helical structure of calcitermin during designing process. First, positively charged Lys 
(K), at position 14, residue was replaced with Gly (G) to obtain a neutral AMP derivative 
VAIALKAAHYHTHGE (0). Then Ala (A), at position 8 was replaced with a negatively charged 
Glu (E) for AMP derivative with a net charge of “-1”, VAIALKAEHYHTHGE. Finally, an Ala 
(A) at position 4 residue was replaced with Glu (E) to obtain an AMP with a net charge of “-2”, 
VAIELKAEHYHTHGE. Each amino acid change was individually confirmed to ensure no 
change in the amphipaticity and the ɑ-helical structure. The helical wheel projection model was 
used to retain protect amphiphilic topology during design studies. These derivatives were also 
checked for their net charges at slightly acidic conditions (pH 5.5) to mimic the CF airways.  
 
5.2.3  Killing effects of calcitermin and its derivatives on planktonic cells at pH 7.4 and  
pH 5.5 
 
To examine the antimicrobial activity of calcitermin and its neutral derivative, the planktonic 
cultures of E. coli HM22, and P. aeruginosa PAO1 were treated. The pH values 5.5 and 7.4 were 
studied to resemble the nasal airway conditions in cystic fibrosis patients and healthy individuals 
respectively. Overnight cultures of each strain were grown in 50 mL LB medium for 12-16 h at 
37°C. Subcultures were then prepared by inoculating LB medium with overnight cultures to an 
optical density at 600 nm (OD600) of 0.01 and harvested when the OD600 reached 0.4-0.5. These 
exponential cultures were divided into two sample groups; to be washed with PBS (pH 7.4) and 
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PBS (pH 5.5 with HCl), and resuspended in the same buffer after washing. For the treatment 
with calcitermin and its neutral derivative, 3 mL of each sample was taken and mixed with 
different concentrations of calcitermin. The samples were incubated for 3 h at 37°C with shaking 
at 200 rpm, and washed three times with PBS at pH 7.4 and pH 5.5. Then a serial dilution of 
each sample was prepared to obtain the concentrations from 1 to 100µg/mL. The cells were then 
washed again and spread on LB agar plates for counting CFU. Each condition was tested with 
three independent cultures. 
 
5.2.4 Persister isolation and calcitermin treatment at pH 7.4 and pH 5.5 
 
To isolate persister cells, overnight cultures of P. aeruginosa PAO1 and exponential cultures of 
E. coli HM22 strains were treated with 200 µg/mL ciprofloxacin (Cip) and 100 µg/mL ampicillin 
respectively for 3 h at 37˚C to kill normal cells as described previously [9,10]. Then the persister 
cells were harvested by centrifugation, washed with PBS at different pH values (pH 7.4 and pH 
5.5 with HCl) three times to remove remaining antibiotic, and resuspended in 20 mL PBS at pH 
7.4 and 5.5. The collected cells were resuspended in 3 mL PBS supplemented with calcitermin at 
different concentrations (from 1 to 100µg/mL). Three replicates were tested for each condition 
and all samples were incubated for 3 h at 37°C with shaking at 200 rpm. After calcitermin 
treatment, the samples were washed with PBS three times and plated to count CFU using drop 
plate method.  
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5.3 Results 
 
5.3.1 New calcitermin derivatives designed with I-TASSER prediction method  
 
Neutral and negatively charged AMP derivatives of calcitermin were successfully designed by 
replacing amino acids guided by helical wheel projections (Fig. 5-1). The amphiphilic topology 
and the helical structure of each derivative were tested with I-TASSER prediction method. Lys 
(K), which is a positively charged amino acid at position 14, was replaced with Gly (G), a neutral 
amino acid, and the net charge of the peptide changed from “+1” to “0” without altering the 3D 
structure of calcitermin.  Besides, changing positions 4 and 8 to Glu (E) was found to protect the 
ɑ-helix conformation (Fig 5-1) but changed the net charge of calcitermin to negative. Besides, 
prediction analysis with I-TASSER suggested a candidate binding region for Ca2+ ions (Fig. 5-
2). This binding region is surrounded by three His (H) at positions 9, 11, 13 and one Tyr (Y) 12. 
In derivative design this Ca2+ion binding region was successfully retained in all calcitermin 
derivatives.  
 
  
 
 
 
 
 
Figure 5-1. A) Helical wheel projection of calcitermin. Modified amino acid positions are 
colored gray. B) Native calcitermin VAIALKAAHYHTHKE (+1), C) neutral derivative 
                                                                  B)                         C)                  D)                     E) 
A)  
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VAIALKAAHYHTHGE (0), D) negatively charged VAIALKAEHYHTHGE (-1), E) negatively 
charged VAIELKAEHYHTHGE (-2). Modified amino acids are underlined along the new net 
charges are shown in parenthesis. 
 
Figure 5-2. Predicted Ca2+ binding site on the native calcitermin from different angles. Green 
sphere represent Ca2+ ion. The blue part, which shows Ca2+ ion binding pocket, is rich with 
amino acids carrying carbon rings in their structures. 
 
5.3.2 Killing effects of calcitermins on planktonic cells  
 
Native calcitermin is effective in killing PAO1 and HM22 cells at pH 5.5 dose dependently. 
However, no significant killing effect was observed when pH in calcitermin treatment elevated to 
pH 7.4 (Fig. 5-3). This is consistent with the in vivo observation that pH is 5.5 in chronic disease 
condition. Calcitermin showed significant killing on both PAO1 and HM22 planktonic cells at 
pH 5.5 when its concentration is increased to 10µg/mL and higher.  
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Figure 5-3. Antimicrobial effect of native calcitermin on the planktonic cells of P. aeruginosa 
PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.  
 
The killing effect of neutral calcitermin derivative on planktonic cells was found different than 
the native calcitermin. Neutral calcitermin derivative showed comparable killing with a dose 
dependence when the experiment pH was adjusted to pH 7.4 (Fig. 5-4). However, this killing 
was not as significant as native calcitermin.  
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Figure 5-4. Antimicrobial effects of neutral calcitermin derivative on planktonic cells of P. 
aeruginosa PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.  
 
5.3.3 Killing effects of calcitermins on persister cells  
 
Even though the total killing is less than normal planktonic cells, native calcitermin was found 
effective against the persister cells of both strains and the effect was stronger at pH 5.5 than pH 
7.4 (Fig 5-5). On the other hand, neutral derivative of calcitermin showed stronger effect on both 
P. aeruginosa PAO1 and E. coli HM22 persister cells at pH 7.4 than pH 5.5 (Fig. 5-6).  
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The killing effect of the neutral derivative on persister cells are rather potent, e. g., 83.35±5.2% 
and 96.54±2.3% of P. aeruginosa PAO1 and E. coli HM22 persister cells were killed at 100 
µg/mL respectively.  
 
     
   
Figure 5-5. Antimicrobial effects of native calcitermin on persister cells of P. aeruginosa PAO1 
and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.  
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Figure 5-6. Antimicrobial effects of neutral calcitermin derivative on persister cells of P. 
aeruginosa PAO1 and E. coli HM22 strains. Both strains were tested at pH 7.4 and pH 5.5.  
 
5.4 Discussion 
 
The amphiphilic topology and ɑ-helical structure were successfully maintained for the new 
calcitermin derivatives by using I-TASSER prediction method. These two physiochemical 
features of this AMP are required for insertion into bacterial cell membrane and for the 
antimicrobial effects [2]. To protect ɑ-helical structure, amino acid changes were made based on 
their ɑ-helix formation propensities. Prediction studies showed that replacing Gly (G) at position 
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14 did not cause any change in the on ɑ-helix structure. This amino acid was chosen to change 
the net charge of new calcitermin derivative since there are only two amino acids with negatively 
charged side chains: Gly (G) and Ala (A). These two amino acids are also members in the family 
of high helix forming propensity amino acids, while the others are with Met (M), Leu (L) and 
Lys (K) [11]. This high helix forming propensity of Gly (G) might have helped the unimpaired 
ɑ-helix structure of new derivatives. However, replacing positions 4 and 8 with Ala (A) caused 
deterioration of the ɑ-helix structures for new designs even though Ala (A) is a high helix 
forming propensity amino acid.  
Another important factor for the antimicrobial effects of calcitermin is the binding of Ca2+ ions, 
which were also demonstrated by I-TASSER predictions (Fig 5-2). The calcitermin sequence is 
equivalent to 15 amino acid carboxyl end of a calgranulin, S100 [5] which are also called 
calcium binding proteins (CaBP) [12]. S100 proteins, involved in Ca2+ homeostasis [13], are also 
found in vertebrates and characterized by two calcium-binding sites with ɑ-helix structures [14]. 
Ion binding regions are known to be important for the function of many peptides [15]. 
Calcitermin derivatives designed with I-TASSER were shown to preserve Ca2+ ion binding 
pocket. Ca2+ ions are also known as important for the integrity of membrane lipid bilayer 
structure [15]. This Ca2+ ion binding capacity of calcitermin might affect stability of the 
membrane since Ca2+ ions are important for membrane integrity. Therefore, calcitermin 
derivatives might still hold potential to bind Ca2+ ions and be effective on the membrane 
stability.  
The amino acids in Ca2+ binding pocket of calcitermin have either 5 carbon ring as in His (H) or 
6 carbon ring as in Tyr (Y). Some Ca2+ binding proteins are known His (H) rich peptides [16]. 
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This suggests that having three His (H) amino acids close to each other within a 5 amino acid 
region is important for the Ca2+ binding ability of calcitermin. During new derivative design 
studies these amino acids involved in Ca2+ binding pocket were retained to protect the Ca2+ 
binding capacity of the peptide.  
It was shown that antimicrobial activity of calcitermin is enhanced in acidic environment (pH 
5.4) [5]. In addition, the native calcitermin, which is positively charged, showed significant 
killing of P. aeruginosa PAO1 and E. coli HM22 cells in exponential cultures only at pH 5.5, but 
not effective at pH 7.4 (Fig 5-3). For example, the killing on P. aeruginosa PAO1 exponential 
cultures by ratios with 10, 50, and 100 µg/mL calcitermin was 49.63±6.24%, 90.72±7.6%, and 
95.27±3.28%, while it showed slightly higher killing effect on E. coli HM22 exponential cells, 
e.g., 66.08±12.07%, 97.07±2.31%, and 99.46±3.98% at the same concentrations. Similar to 
planktonic cells, native calcitermin showed comparable effects on persister cells; better killing at 
pH 5.5 while no clear effect was observed at pH 7.4 (Fig 5-5). For example at 50 and 100 
µg/mL, calcitermin was able to kill 25.29±3.57% and 48.82±3.6% P. aeruginosa PAO1 persister 
cells respectively. Persister cells of E. coli HM22 showed similar susceptibility to native 
calcitermin and the killing was 34.1±3.8% and 60.13±9.7% at 50 and 100 µg/mL respectively. 
Even though it is less effective than killing normal planktonic cells, the killing effect of native 
calcitermin on persister cells holds a potential, which might be further improved via co-treatment 
with other antibiotics. Besides comparable killing effects of native calcitermin on the normal and 
persister cells of both strains, a general mechanism of action might be cell membrane targeting 
since E. coli is more susceptible to antibiotics in general [17].  
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The neutral calcitermin derivative did show strong killing effect on normal planktonic cells of P. 
aeruginosa PAO1 and E. coli HM22 at pH 7.4 compared native calcitermin. However, this new 
derivative showed similar effects at pH 7.4 and pH 5.5. For example, 100 µg/mL neutral 
calcitermin derivative killed 35.71±3.52% and 45.41±5.71% of normal planktonic PAO1 cells at 
pH 5.5 and pH 7.4 respectively. Similarly, the neutral calcitermin derivative showed slightly 
better killing effect on E. coli HM22 planktonic cells at pH 7.4 compared to pH 5.5; e.g., 
28.33±5.97% and 48.62±2.96% with pH 5.5, and 42.18±8.72% and 60.46±6.3% with pH 7.4, at 
50 and 100µg/mL, respectively. The trend of less killing effect at lower pH diminished when the 
neutral calcitermin derivative was tested on persister cells of P. aeruginosa PAO1 and E. coli 
HM22. However, a significantly higher killing effect with pH 7.4 on persister cells compared to 
planktonic cells of both strains was observed when treated with neutral calcitermin derivative. 
For example, 10, 50, and 100 µg/mL neutral calcitermin showed 31.3±8.23, 62.22±7.1%, and 
83.35±5.2% killing of PAO1 and 42.37±5.08%, 72.58±1.92%, and 96.54±2.3% killing of HM22 
respectively.  
Persister cells provide a reservoir for recurring infections [18]. As an effective AMP at pH 7.4, 
which is the pH level of nasal airways in healthy people, calcitermin might be able to eliminate 
persister cells before the infection becomes chronic. Another important outcome from this study 
is the finding that the neutral derivative is more effective on persister cells than its positively 
charged native form. We expect that other AMPs can be engineered following this principle to 
achieve better control of chronic infections. Besides, the higher killing effect of neutral 
calcitermin derivative on persister cells might be further improved by combining it with the 
native form or via co-treatment with other antimicrobial agents so that both normal and persister 
cells can be eliminated.   
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As alternative antimicrobials, AMPs have advantages since these compounds attack bacterial 
membranes and thus have a broad spectrum of targeting microbes. Cell membrane is present in 
all bacteria with a relatively simple bilayer structure. The functions of membrane embedded 
proteins that are essential for the survival of bacteria and the rapid action of AMPs leave little 
room for bacteria to develop resistance. These properties led to growing interest in AMP 
research and some novel lead compounds have shown great potential for infection control. 
However, the lack of a methodology for rational AMP design, high production cost, 
susceptibility to proteolytic degradation, potential toxicity to eukaryotic cells and low specify for 
a given bacterial species are the major challenges in AMP development which need to be 
addressed in new design studies. Therefore, more research on the mechanisms of AMP killing an 
the design of synthetic AMPs are required.  
Up to date, most of the AMP studies focused on planktonic cells. Treatment of biofilms and 
persister cells, that are highly resistant to traditional antibiotics, with AMPs is still an 
understudied area. Through collaboration with the Kallenbach lab at New York University, we 
tested the newly designed synthetic AMPs for their activities against bacterial cells at different 
physiological stages including normal planktonic cells, persister cells and biofilms.  
RW rich peptides are known to be effective on bacterial cells. Here we demonstrated that 2D-24, 
a new RW rick dendrimer with a branched core is effective on multidrug-tolerant persister cells 
of P. aeruginosa PAO1 and PDO300 in a dose dependent manner with no toxicity to eukaryotic 
cells at the effective concentrations. Besides, changing the net charge of calcitermin from +1 to 
neutral resulted in a better killing of persister cells at neutral pH. Triazine derivatives were also 
proven effective on normal planktonic and persister cells as well as biofilm cells (in the presence 
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of alginate lyase). These results show that AMPs can be engineered with optimized structure for 
better killing of multi-drug tolerant bacteria at different physiological stages. It is also possible to 
achieve synergy with conventional antibiotics in bacterial killing with lowered cytotoxicity to 
eukaryotic cells. 
The structure-function relation of effective AMP derivatives at different pH values and cellular 
stages might be studied to further develop AMPs for different clinical applications. 
In addition to membrane targeting AMPs, we also tested some antibiotics that are substrates of 
efflux pumps on persister cells. Erythromycin was found effective on E. coli HM22 persister 
cells, although the normal planktonic cells are resistant to this antibiotic. This antibiotic is a 
known substrate of the efflux pump AcrAB and these pumps are active in normal planktonic 
cells. For persister cells, these efflux pumps are inactive and erythromycin molecules can 
accumulate in cytoplasm. The strong binding between erythromycin and bacterial ribosome may 
lead to killing of persister cells during wake-up process. 
Human originated AMPs are a great source for developing new control agents to treat different 
infections. Different physiological conditions of different tissues might limit or hinder the 
effectiveness of a particular AMP for certain infections. Therefore, designing different AMP 
structures specific for different tissues will be a useful strategy for future studies.  
In addition to the bacterial killing, the diverse antimicrobial and structural properties of AMPs 
make them a convenient tool for other biological applications such as drug delivery vehicles. The 
close interaction between AMP with membrane can be used to deliver other therapeutic agents 
through the membrane. For example chloramphenicol requires active transport for cellular 
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uptake. These transport mechanism are expected to be inactive in persister cells. Using AMP-
chloramphenicol hybrids to deliver these drugs to persister cells may lead to enhanced 
antimicrobial activity. Thus, understanding the biological and structure properties of AMPs and 
their interaction with bacterial membranes is important for developing peptide-based 
therapeutics. 
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Microscopy: GFP; 3D Z-stack imaging; Scanning electron microscopy; Transmission electron 
microscopy. 
Bioinformatics: Mass DNA data analysis from Next Generation Sequencing; BLAST; 16SrDNA 
sequence analysis; Primer design; Peptide modification; Peptide structure predictions. 
Cell sorting & Flow cytometry: Bacterial viability analysis at individual cell level; 
Compensation; Troubleshooting; Nozzle size selection; PSI selection. 
 
Teaching and Mentoring 
 
Lab Manager, 2010 –2014   
Biofilm Laboratory, Biomedical and Chemical Engineering Department, Syracuse University. 
 
Trained new graduate students on basic laboratory regulations, and aseptic techniques. 
 
Trained lab members on following topics; DNA isolation, PCR primer design, Quality 
check of primer sets, DNA annealing, DNA alignment & Clustal analysis, Real-time 
PCR, Melting curve analysis, Agarose gel and western blot imaging and analysis, Basic 
trouble shooting for DNA studies, DNA  recombination studies.  
 
NSF REM Mentoring, Summer 2011, 2011, 2012, 2013, 2014   
Biomedical and Chemical Engineering Department, Syracuse University. 
 
Trained a high school student, 3 high school teachers and 4 undergrad students to manage 
complex science projects and helped them to gain experience on how to design a 
scientific experiment and data reporting.   
 
Biotechnology Workshop Committee Chair, June 2008  
Biology Department, Karadeniz Technical University. 
 
Organized “National Biotechnology Spring Course” with undergrad students to help them 
for their future career, by showing how to choose trend topics on science and how to see 
opportunities in their future careers in molecular biology and microbiology fields. 
 
Graduate Teaching Assistant, 2003-2008 
Biology Department, Karadeniz Technical University. 
 
